1 REVIEW ARTICLE

2 How should we be using biomarkers in trials of disease
3 modification in Parkinson's disease?

4 Nirosen Vijiaratnam and Thomas Foltynie

5 Abstract

6 The recent validation of the alpha synuclein seed amplification assay as a biomarker with high
7 sensitivity and specificity for the diagnosis of Parkinson's disease has formed the backbone for a
8 proposed staging system for incorporation in Parkinson's disease clinical studies and trials. The
9 routine use of this biomarker should greatly aid in the accuracy of diagnosis during recruitment
10 of Parkinson's disease patients into trials (as distinct from patients with non- Parkinson's disease
11 parkinsonism or non- Parkinson's disease tremors). There remain however further challenges in
12 the pursuit of biomarkers for clinical trials of disease modifying agents in Parkinson's disease,
13 namely: optimising the distinction between different alpha synucleinopathies; the selection of
14 subgroups most likely to benefit from a candidate disease modifying agent; as sensitive means of
15 confirming target engagement; and in the early prediction of longer-term clinical benefit. For
16 example; levels of cerebrospinal fluid proteins such as the lysosomal enzyme ß-
17 glucocerebrosidase may assist in prognostication or allow enrichment of appropriate patients into
18 disease modifying trials of agents with this enzyme as the target; the presence of coexisting
19 Alzheimer disease like pathology (detectable through cerebrospinal fluid levels of Amyloid
20 Beta-42 and tau) can predict subsequent cognitive decline; imaging techniques such as free-water
21 or neuromelanin MRI may objectively track decline of Parkinson's disease even in its later
22 stages. The exploitation of additional biomarkers to the alpha synuclein seed amplification assay
23 will therefore greatly add to our ability to plan trials and assess disease modifying properties of
24 interventions. The choice of which biomarker(s) to use in the context of disease modifying
25 clinical trials will depend on the intervention, the stage (at risk, premotor, motor, complex) of the
26 population recruited and the aims of the trial. The progress already made lends hope that panels
27 of fluid biomarkers in tandem with structural or functional imaging may provide sensitive and
28 objective methods of confirming that an intervention is modifying a key pathophysiological

1 process of Parkinson's disease. However, correlation with clinical progression does not

2 necessarily equate to causation and the ongoing validation of quantitative biomarkers will

3 depend on insightful clinical-genetic-pathophysiological comparisons incorporating longitudinal

4 biomarker changes from those at genetic risk with evidence of onset of the pathophysiology and

5 those at each stage of manifest clinical Parkinson's disease.

6

7 **Author affiliation:**

8 Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of

9 Neurology, London, WC1N 3BG, UK

10

11 Correspondence to: Professor Thomas Foltynie

12 Department of Clinical and Movement Neurosciences

13 UCL Queen Square Institute of Neurology

14 London, WC1N 3BG, UK

15 E-mail: t.foltynie@ucl.ac.uk

16

17 **Running title**: PD disease modification biomarkers

18

19 **Keywords:** Parkinson's disease,; biomarkers; disease modification; clinical trials

20 **Abbreviations:** AADC=L-aromatic amino acid decarboxylase; α-synuclein=alpha-synuclein; α -

21 syn SAA=α-synuclein seed amplification assay; Aβ=Amyloid beta peptides; AD=Alzheimer's

22 disease; APOE4=apolipoprotein E; APP=amyloid precursor protein; AUC=area under the curve;

23 CTSD=cathepsin D; CBS=corticobasal syndrome; CCL5= chemokine ligand 5; CNS=central

24 nervous system; CNTN-1=Contactin-1; CRP: C-reactive protein; DAT=dopamine transporter;

25 DBM=Deformation-based morphometry; DJ-1=deglycase; DOPA=3,4-dihydroxyphenylalanine;

26 DOPAC=3,4-dihydroxyphenylacetic acid; DLB=dementia with Lewy bodies; DNH=dorsal

27 nigral hyperintensity; ET=essential tremor; EVs=extracellular vesicles; GBA1=Glucosidase beta

1 acid 1; GCase=B-glucocerebrosidase; GAP-43=growth associated protein

2 43;GI=gastrointestinal; GFAP= Glial fibrillary acidic protein; HbA1c= glycated hemoglobin;

3 HC=healthy controls; 5-HIAA=5-hydroxy-3-indoleacetic acid; HOMA-IR= Homeostatic Model

4 Assessment for Insulin Resistance; HVA=homovanillic acid; HY=Hoehn and Yahr;

5 IMR=immunomagnetic reduction; Il= Interleukin; IRS-1=insulin-receptor substrate-1; IRS-1 p-

6 Tyr= tyrosine-phosphorylated insulin receptor substrate-1; LN=lentiform nucleus;

7 LRRK2=Leucine-rich repeat kinase 2; MCP-1=monocyte chemoattractant protein-1; miRNA=

8 MicroRNA; MSA=multiple system atrophy; NAA/Cr=N-acetyl aspartate/creatine;

9 ncRNA=Noncoding RNAs; NfL=neurofilament light chain; NFTs=neurofibrillary tangles; NLR:

10 Neutrophil-to-lymphocyte ratios; Ng= neurogranin; NMI=Neuromelanin imaging;

11 PD=Parkinson's disease; PDCP=PD-related cognitive pattern; PDD=Parkinson's disease

12 dementia; PDRP=PD-related pattern; PET=Positron Emission Tomography; PGC1=Peroxisome

13 proliferator-activated receptor γ coactivator 1; Pink-1=PTEN induced kinase 1; PIGD= postural

14 instability and gait disorders; PLA= Proximity Ligation Assay; PMCA= Protein misfolding

15 cyclic amplification; MRS=magnetic resonance spectroscopy; 31P-MRS= Phosphorus based

16 magnetic resonance spectroscopy; PPMI= Parkinson's progression markers initiative;

17 PRKN=Parkin RBR E3 Ubiquitin Protein Ligase; pSer65Ub=phosphorylated ubiquitin residue at

18 the serine 65; PSP=progressive supranuclear palsy; p-tau=phosphorylated tau; QSM=quantitative

19 susceptibility mapping; RT-QuIC=real-time quaking-induced conversion; Ser-129p-α-

20 syn=Phosphorylated α-synuclein at serine-129; SCFA=short-chain fatty acids; SN=Substantia

21 Nigra; SNARE= soluble N-ethylmaleimide sensitive factor attachment protein; SNAP-

22 25=synaptosomal-associated protein 25; sncRNA=small ncRNA; SNP=single nucleotide

23 polymorphism; SPECT= single photon emission tomography; SWEDDS=scans without evidence

24 of dopaminergic deficit; SWI=susceptibility- weighted imaging; t-tau=total tau; T2DM=Type 2

25 diabetes mellitus; TSPO=translocator protein; VAMP=vesicle-associated membrane proteins;

26 VBM=voxel-based morphometry; VMAT2=vesicular monoamine transporter 2; YKL-

27 40=chitinase-3-like protein 1

28

1 Introduction

2 Modifying the relentless deteriorating course of Parkinson's disease (PD) remains a critical yet
3 currently elusive goal. Despite decades of trials evaluating promising candidates, no treatments
4 have yet been proven to achieve this. While this may be due to lack of trial evaluation of truly
5 effective agents, other potentially contributing factors include imprecise patient selection,
6 inadequacies in trial design, failure to confirm target engagement, and the absence of objective
7 measures of disease progression [1].

8

9 One way of improving likelihood of success is by identifying better biomarkers. A biomarker is a
10 characteristic that is objectively measured and evaluated from any substance, structure, or
11 process that can be measured in the body or its products as an indicator of normal biological or
12 pathogenic processes, or pharmacologic responses to a therapeutic intervention [2]. An ideal
13 biomarker should be readily quantifiable in accessible clinical samples (clinical assessments,
14 biofluids (blood, cerebrospinal fluid (CSF), urine, saliva, tears, stool), imaging) and tissues (skin,
15 oro-gastrointestinal mucosa)) while being reliable, quick, and inexpensive.

16

17 Suboptimal patient selection in disease modifying trials may be related to poor diagnostic
18 accuracy. Pathological modification (phosphorylation and conformational transformation) of the
19 physiological protein, alpha-synuclein (α-synuclein) to misfolded oligomeric and fibrillary forms
20 is the most consistent pathological feature of PD [3]. The accumulation and interplay of these
21 abnormal protein forms with the organelles/cellular pathways involved in their clearance as well
22 as normal cellular maintenance and survival results in neuronal dysfunction and ultimately
23 axonal injury and neuronal death.

24

25 The α-synuclein seed amplification assay (α -syn SAA) has high sensitivity and specificity for
26 PD diagnostic accuracy with a recent study of >1100 samples from the PPMI cohort[4] further
27 confirming pre-existing evidence for its use[5-11], and is now proposed as a core aspect of a
28 potential staging system for PD[12,13]. This is potentially a pivotal step in clarifying eligibility
29 criteria for inclusion in trials and distinguishing PD patients from those with atypical forms of

parkinsonism. While needing further clarification, the α-syn SAA is at the present time largely a binary measure simply indicating the presence/absence of the pathophysiological process of alpha synuclein aggregation and cannot yet be used to track disease severity which instead relies on clinical measurements.

As such there is still a need for additional biomarkers that might enrich treatment arms for PD subgroups most likely to respond and allow early exploratory analyses according to engagement of the therapeutic with its putative target. Current trials typically rely on clinical end points with scales and questionnaires which are subject to inter-rater variability while potentially being confounded by symptomatic drug effects. Evaluations using scales may also be compromised by non-linear changes over time [14], may be limited by reduced compliance, recall bias and fatigue [15], sometimes do not correlate sufficiently with quantitative objective assessments [16,17] and vary in their sensitivity at different disease stages [18,19] raising questions about inclusion of patients who may have progressed beyond the salvageable period.

Biomarkers that are robustly demonstrated to track disease progression and treatment effects could potentially shorten periods of assessment and reduce the number of patients required for preliminary demonstration of efficacy. Ideally, short-term changes in the biomarker should anticipate long-term clinical outcomes. Furthermore, by confirming target engagement by the dose(s) of the agent under study, biomarkers can be used to improve the distinction between an intervention's disease-modifying effects from purely symptomatic improvements. While there are parallel efforts exploring additional biomarkers for PD prior to clinically manifest disease, in this review, we will discuss the current state of fluid, tissue and imaging biomarker development in clinically established PD and their potential for use either alone, or in combination in future disease modifying clinical trials.

1 Fluid and tissue biomarkers

2 Box 1 outlines techniques that have been used to measure different alpha-synuclein forms as well
3 as other protein/enzyme levels that reflect cellular pathway abnormalities that can be measured
4 in biofluids.

5

6 Alpha synuclein

7 Total, phosphorylated and oligomeric α-synuclein levels and their ratios in CSF, blood and other
8 body fluids and tissues have all been explored for biomarker use. (Table 1)

9

10 *Distinguishing PD from other conditions*

11 Total free α-synuclein levels have been explored in CSF, plasma/serum, saliva and
12 submandibular gland tissue and are of no diagnostic value in PD[20-29]. Measurement of total α-
13 synuclein levels in extracellular vesicles (EVs) either in CSF [30], plasma/serum [31-38] or saliva[39]
14 can distinguish PD from controls[32-36,38,40-42]. Total α-synuclein levels in EVs derived from
15 neurons can also distinguish PD from atypical disorders though best distinction is achieved when
16 α-synuclein levels are combined with levels of other proteins such as clusterin[35,43]. Similarly,
17 differences in α-synuclein levels in neuronal compared to oligodendroglial derived EVs shows
18 promise for distinguishing PD from MSA[37]. Phosphorylated α-synuclein at serine-129 (Ser-
19 129p-α-syn) levels are elevated in PD patients' CSF [24,44-47], serum and plasma[48-51] though similar
20 elevations are seen in atypical parkinsonian conditions, limiting specificity/diagnostic use [52-55].
21 Elevated levels are similarly seen for Ser-129p-α-syn in skin [29,56-60]. A predilection for Ser-129p-
22 α-syn deposition in autonomic compared to somatosensory nerve fibres and proximal to distal
23 gradients could be applied for improving distinction of PD from MSA-P[61,62].

24 Levels of α-synuclein oligomers are also increased in the CSF [27,47,63-67], plasma [68,69], RBCs [70,71],
25 saliva and tears [28,63,72-77] of PD patients (although again with a few teams reporting contradictory
26 findings [66,78,79]). Oligomeric CSF α-synuclein levels taken alone however have unsatisfactory
27 diagnostic properties [24]. Combining oligomeric α-synuclein and aggregated tau measurement in
28 serum neuronal derived exosomes seems to distinguish PD from tauopathies well[80]. Reliable

quantification and differentiation approaches between protein species (oligomers, fibrils and other aggregated forms) are currently lacking [50,52]. Making these distinctions will be critical in improving the diagnostic performance of aggregated forms considering unique patterns have been noted in different synucleinopathies [81,82]. Ratios of Ser-129p-α-syn and or oligomeric α-synuclein to total α-synuclein are elevated in PD and seem most promising in overcoming limitations of individual markers for differentiating synucleinopathies [44,45,53,54,65,67,83 84].

Seed amplification assays such as real-time quaking-induced conversion (RT-QuIC) and Protein misfolding cyclic amplification (PMCA) are arguably the most important achievement in the field of biomarkers to date and will likely be the most useful diagnostic biomarker for trials. These techniques can amplify and detect minute amounts of aggregated α-synuclein in CSF [10,85-87]. Studies comparing brain and CSF samples have demonstrated excellent performance for distinguishing PD from HC (sensitivity and specificity (90%–100%)) [4-11] with comparable results for both seeding methods [7,10] across laboratories [10]. Assays can also distinguish PD from non-synuclein disorders such as Progressive supranuclear palsy (PSP) and Corticobasal syndrome (CBS) [11] though accuracy for distinguishing multiple system atrophy (MSA) from these conditions is poor (sensitivity 4%–82%) while studies exploring α-syn SAA to distinguish MSA from PD have also reported variable findings[86-90]. As differences in α-synuclein strains and therefore biochemical, morphological, and structural properties of the final α-syn SAA reaction products underlie PD and MSA phenotypic heterogeneity, different outcomes may be explained by the fact that different chemical environments (SAA reaction mixes) can differentially influence formation and growth of different strains. Protocols optimized for PD may not therefore work so well for MSA detection[11,91].

In attempts to avoid lumbar puncture, α-syn SAA has been explored in samples obtained through less invasive approaches. Increased α-synuclein *skin* seeding activity has been observed in PD (post-mortem and living) patients with excellent distinction from non-neurodegenerative cases [92] while aggregation rates using RT QuIC correlate with cognitive and motor status [8]. Similarly, seeding activity in *submandibular gland* tissue of PD patients has been noted though sensitivity (73.2% vs 100%) and specificity (78.6% vs 94%) for distinguishing PD from HCs varies

between studies [93,94] while preliminary findings in saliva are also promising[95]. A recent report demonstrating excellent ability of *serum* immunoprecipitation-based RT-QuIC for distinguishing PD from HC may herald a new approach towards diagnosing PD through a simple blood test though lower detection rates in MSA, likely due to technical factors, will still need to be overcome[96]. Similarly, the demonstration of seeding activity from pathological α-synuclein derived from plasma EVs is also promising [97]. The use of less invasive samples will be ideal for trial recruitment, (given feedback from patients regarding tolerability of submandibular gland biopsy) but will require demonstration of comparability with the high sensitivity and specificity achieved with CSF (although a recent meta-analysis suggests comparability between CSF and skin for diagnostic purposes[89,98]).

Predicting severity phenotypes and measuring progression

Total free α-synuclein levels do not correlate with disease severity and their ability to predict and track progression is also poor [21,24] [48] . EV total α-synuclein levels also predict and track progression in PD poorly [30,31,34,35,99,100].

While Ser-129p-α-syn levels do seem to reflect disease severity [44,45,101] and motor symptom progression[102] an inverse relationship in later disease (potentially as a result of extensive neuronal damage) [52,103] makes its use as a progression biomarker challenging if applied to trials with long term follow up or involving patients with established disease. CSF and serum levels of a number of other phosphorylated α-synuclein species have also been explored though preliminary findings are somewhat conflicting [104] [105] [106]. A rostro-caudal pSer129-α-syn deposition gradient in the gastrointestinal (GI) tract of PD patients has also been noted, reflecting neurodegeneration in the myenteric plexus [107,108] although this may be a reactive physiological phenomenon[109]. Disentangling reactive from pathological components will be important as deposition may occur here earlier and therefore guide earlier treatment in early motor stages where diagnostic criteria have yet to be fully fulfilled.

Oligomeric CSF α-synuclein levels can also reflect PD severity and progression [46,53,101,103] despite some contradictory evidence[110] though previously highlighted limitations of differentiating aggregated forms need to be addressed. Longitudinal measurement of Ser-129p-α-syn and or oligomeric to total α-synuclein ratios might detect effective treatment responses [44,45,53,65,67,83,101]. Similar findings have also been observed when measuring these ratios in serum and salivary EVs, although this does not seem to bring additional value[34,35,38,84,111,112].

Correlation of α-syn SAA with disease severity and progression is unclear and specific kinetic cut-offs remain elusive, though quantification of α-syn SAA end products with oligomer-specific ELISA may be helpful in this regard [10,113,114]. Taken together, the best α-synuclein candidate biomarkers for diagnosing PD to consider for clinical trials is to use α-syn SAA. The ratios of Ser-129p-α-syn and or oligomeric α-synuclein to total α-synuclein can also helpfully differentiate between synucleinopathies [44,45,53,65,67,83], and are credible markers for tracking progression.

Alzheimer disease (AD) like biomarkers

Amyloid beta (Aβ) peptides are cleaved from the amyloid precursor protein (APP) into the peptides Aβ42 and Aβ40 which can form extracellular amyloid plaques [115,116]. Tau proteins comprise highly soluble isoforms while their hyperphosphorylation contributes to the development of neurofibrillary tangles (NFTs) [117]. Amyloid plaques are abundant in the central nervous system (CNS) alongside NFTs in Alzheimer's disease (AD) while NFTs are characteristic of progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) [118,119].

Distinguishing PD from other conditions

Biomarkers reflecting tau and amyloid pathology can be measured in CSF and blood and include free and EV levels of total tau (t-tau), phosphorylated tau (p-tau) and amyloid peptide isoforms (Aβ42 and Aβ40). Higher CSF t-tau and decreased Aβ42 levels occur in tauopathies. This combination best distinguishes PD from CBS though the relative rarity of this condition makes widespread testing in PD trials of modest value[120,121]. Preliminary evidence suggests

ultrasensitive tau SAA may identify/exclude patients with tauopathies from PD at trial recruitment [122] though a combined assay with α-synuclein would be more ideal.

The combination of reduced Aβ42 and increased t-tau and p-tau levels is collectively termed "an AD-like profile" considering its specificity for diagnosing the condition [123]. This profile occurs in a larger proportion of synucleinopathy patients with prominent cognitive dysfunction (i.e. Parkinson's disease dementia (PDD) and Dementia with Lewy bodies (DLB)) [124-126]. CSF AD-like biomarkers may therefore be useful for differentiating DLB from other parkinsonian disorders, although for some interventional trials this distinction may be somewhat arbitrary. Levels of total and phosphorylated tau are increased in all parkinsonian disease groups and combining them with Aβ42 only usefully differentiates PD from frontotemporal dementia [127]. Taken together these findings suggest free blood levels of these markers are unlikely to be of diagnostic value in trials.

Predicting severity phenotypes and measuring progression

Tau and AD pathology commonly coexist in synucleinopathy patients[128] and correlate with an acceleration of cognitive decline[129,130]. PD patients with lower CSF Aβ42 levels at disease onset also have earlier appearance of cognitive impairment and more rapid conversion to PD related dementia [67,131,132]. The measurement of CSF Aβ42 could therefore be of prognostic value by reflecting brain amyloid content even prior to apparent clinical cognitive impairment[133].

Although Aβ42 and tau can also be measured in blood, levels correlate poorly with cerebral pathology [134] potentially due to extra-cerebral sources such as platelets. Ultrasensitive immunoassay technologies such as immunomagnetic reduction (IMR) improves this [135] though correlation with cognitive function has been inconsistent [127,136,137]. Similarly, total tau protein blood findings have been variable [136,137] potentially due to rapid changes in blood concentrations [138], although higher t-tau levels seem to correlate with lower cognitive performance [139],

Aβ42 and tau can also be detected in EVs. While also not of diagnostic value, elevated levels in combination with elevated a-syn[140,141] and lower serine phosphorylated Insulin receptor substrate (IRS-p312) which is a marker of neuronal insulin resistance in blood EVs [142], predicts worse motor and cognitive dysfunction progression phenotypes well. Larger replication studies of Aβ

and tau in EVs are needed to better assess their validity for predicting cognitive dysfunction in PD before adoption for widespread use.

Measurement of other phosphorylated tau species (P-tau181, P-tau217, and P-tau231) in CSF and plasma can discriminate AD patients from cognitively unimpaired subjects and reflect cognitive measures and progression[143]. P-tau181 levels have been studied in PD and their ability to predict disease severity and cognitive decline has been mixed and therefore cannot currently be recommended for trial use[144-146]. Other tau species also show promise in AD and need further exploration in PD cohorts.

Neuroinflammation

Immune cells in the CNS and in the periphery are involved in PD neurodegeneration[147]. Measurement of cellular components and levels of inflammatory mediators have therefore been explored for biomarker purposes. (Table 2) Glial fibrillary acidic protein (GFAP) is released from astrocytes into the bloodstream and its level can be used to distinguish PD from HC, [148,149] while its ability to discriminate PD from other atypical parkinsonisms is unclear. The glial activation biomarkers YKL-40 (chitinase-3-like protein 1) and MCP-1 (monocyte chemoattractant protein-1) are increased even further in atypical parkinsonian patients compared to PD and can thus reliably discriminate tauopathies from synucleinopathies [150,151] though this is best achieved by combining them with a panel of non-inflammatory CSF biomarkers (AUC = 0.95) [152]. Within PD patients, GFAP levels seem to predict the development of dementia[153]

Neutrophil-to-lymphocyte ratios (NLR) are indicative of overall inflammatory status and are elevated in PD compared to healthy controls [154] as is a proinflammatory lymphocyte profile (diminished T regulatory and increased T helper cell levels) [155] [156-158]. NLR has been negatively associated with presynaptic radionuclide striatal-binding ratios and positively associated with motor impairment [154,159,160] while a proinflammatory lymphocyte profile shift is associated with more severe motor and cognitive impairment [161,162] and an increase in Tregs expressing CD49d is linked to lesser motor impairment [163]. Altered lymphocytes lead to and are in turn influenced by cytokines. Elevated C-reactive protein (CRP), Interleukin (Il) 6 and Il-10 as well as tumour

necrosis factor α and chemokine ligand 5 (CCL5, RANTES) levels have been noted in PD [164-172]. Current evidence does not however suggest these markers would help in distinguishing PD from atypical conditions considering inconsistent findings between studies[157,173-175] and small-to-intermediate effect sizes [176]. Similarly, associations with non-motor symptoms noted particularly for Il-6 and IL-10[177] are unlikely to be of value for trial design though associations of pro-inflammatory cytokines particularly CRP and CCL5 with reduced survival [178] and the development of motor and cognitive impairment[179-181] is of value for both prognosis and monitoring progression.

Taken together, the value of individual inflammatory markers is low, although combining several inflammatory markers for predicting disease progression will likely contribute to future approaches[181,182]. While better validated general biomarkers of progression exist, these panels could be particularly useful at enriching trials testing agents targeting inflammatory pathways.

Genetics and gene regulation

The relationship between genetic risk factors for PD, and the pathophysiological processes underlying PD are under renewed scrutiny based on the use of α-syn SAA in CSF. People with Leucine-rich repeat kinase 2 (LRRK2) mutations may develop typical PD, positive α-syn SAA in CSF and typical PD pathology at post mortem[183], while the phenotype, pathophysiology and α-syn SAA findings and post mortem pathology can also be completely different despite the same LRRK2 mutation[184]. The far lower rates of positivity of the CSF α-syn SAA among LRRK2 mutation carriers, questions whether to include *LRRK2* mutation carriers within trials targeting alpha synuclein specifically, and potentially other broad interventions being considered for PD neurodegeneration.[185] Nevertheless there is great interest in targeting LRRK2 as a means of influencing disease progression in PD, and genetic status may be of greater relevance for these interventions than other biomarkers. That said, the most advanced LRRK2 inhibitor trial has pragmatically chosen to focus recruitment of a combination of PD patients with and without LRRK2 mutations (NCT05348785), while other LRRK2 specific interventions may specifically want to recruit the subgroup who are positive for the α-syn SAA.

1

Of relevance to this point, molecular dysfunction of pathways downstream from *LRRK2* also occur and these are being explored as biomarkers in trials targeting this enzyme. pS1292-LRRK2 levels are higher in urinary EVs in idiopathic PD and correlate with motor severity [186]. Furthermore, CSF EV pS1292-LRRK2 levels are ten-fold higher than urinary EV levels suggesting relevance for CNS activity [187]. Genetic variability may therefore be considered for selecting patients for precision medicine interventions as well as for helping balancing trial arms for progression, or adjusting for baseline differences in longitudinal analysis. pS1292-LRRK2 levels or other downstream molecular abnormalities (whole-blood pS935 LRRK2 levels, peripheral blood mononuclear cell pT73 Rab10 levels, urine di-22:6-bis (monoacylglycerol) phosphate, and CSF total LRRK2) may become useful tools for measuring target engagement and therapeutic response to agents specifically targeting these pathways as has been demonstrated in a recent early stage LRRK2 inhibitor trial[188] (Supplementary Table 1).

Other genetic factors can also determine phenotypic severity and progression. PD patients with the A53T alpha synuclein mutation experience worse autonomic and cognitive deterioration [189] while apolipoprotein E gene (APOE4) and Glucosidase beta acid 1 (GBA1) PD patients have accelerated cognitive [190-194] and motor deterioration [195] though this may be constrained to specific mutations/polymorphisms [196-198]. Polygenic risk scores for predicting rate of progression appear promising although need replication[199,200].

Noncoding RNAs (ncRNA) contribute to gene expression regulation. MicroRNA (miRNA) are small ncRNA (sncRNA) which have been explored for biomarker potential. Unique serum miRNA patterns comprising upregulation (miR-6836-3p and miR-6777-3p) and downregulation (miR-493-5p, miR-487b-3p, and miR-15b-5p) have been noted in PD [201] [202] and supported by known involvement of these miRNAs in PD pathogenic processes. Sampling, quantification, and analysis approaches need to become standardised to facilitate between study comparisons. SncRNA analysis from CSF EVs may also be worth further exploration [203]. While plasma EV miRNA measurement appears useful when distinguishing PD from HC (AUC 0.85 (miR331-5p) and 0.90 (miR-505) [204]), the combination of miR153 and miR-409-3p using the CSF EV

approach is even more impressive (AUC 0.99) [205]. miRNAs may likely play a diagnostic role in future trials depending on the mode of action of the drug being studied.

Lysosomal dysfunction

The GBA1 gene encodes the lysosomal enzyme β-glucocerebrosidase (GCase). GBA1 mutation carriers have almost uniformly positive α-syn SAA in CSF[4]. Impaired GCase and other lysosomal enzyme activity (e.g. cathepsin D (CTSD)) in GBA1-carrier and non-carrier PD patients leads to lysosomal dysfunction thus negatively impacting α-synuclein degradation [206,207]. Although CSF GCase activity depends on the specific GBA1 mutation carried, levels are also lower in idiopathic PD patients compared to controls[208]. GCase levels are however of low value for diagnosing PD though combining GCase activity with oligomeric/total α-synuclein ratios (AUC = 0.87, 82% sensitivity, 71% specificity) as well as other lysosomal enzymes (CTSD and β-hexoxaminidase), and Aβ-42 improves this (AUC = 0.83, 75% specificity, 84% sensitivity) [209].

CSF GCase levels correlate with cognitive impairment[210] while activity also seems to predict subsequent development of dementia regardless of genetic status[211]. CSF GCase levels may therefore usefully allow enrichment of clinical trial arms testing agents targeting this enzyme (even in the absence of a GBA1 mutation) as well as a method for confirming target engagement. Blood GCase activity is also reduced compared to HC though prediction of progression has not been explored[212,213]. GCase activity is being used as an exploratory outcome in recent disease modification trials in conjunction with its downstream hydrolytic product glucosylceramide. (Supplementary Table 1) Glucosylceramide can distinguish GBA-PD from idiopathic PD and HC and be measured in both plasma and peripheral blood mononuclear cells and therefore used as a biomarker for target engagement in clinical trials targeting GBA-PD[214,215].

Mitochondrial dysfunction

Mitochondrial dysfunction contributes to the pathogenesis of PD[216]. The existence of inherited autosomal recessive parkinsonism due to mutations of Parkin (PRKN), PTEN induced kinase 1

1 (Pink-1) and the protein deglycase (DJ-1) gene which encode proteins that mediate mitophagy

2 supports this link[217,218] . Typical α-synuclein pathology is less consistently reported in people

3 with these mutations and the rate of positivity of the α-syn SAA in CSF is also low[96,185] thus

4 reinforcing the potential importance of both genetic testing and selection of additional other

5 biomarkers during trial recruitment and follow up, depending on the mode of action of the agent

6 being tested.

7 The best explored mitochondrial biomarker in this context is CSF DJ-1, levels of which are

8 decreased in PD[219,220] compared to controls and correlate with disease severity[20] though

9 similarities with other parkinsonian syndromes make its diagnostic use unlikely [221,222]. Similar

10 poor diagnostic value has been noted for serum and plasma DJ-1 levels[223-225]. Other less well

11 studied biomarkers include phosphorylated ubiquitin at the serine 65 residue (pSer65Ub) which

12 occurs by virtue of loss of the mitochondrial membrane potential triggering the stabilization of

13 Pink1 at the outer mitochondrial membrane[226]. While increased pSer65Ub levels have been

14 observed in PD post-mortem brains, lower levels have been identified in familial PD with

15 Pink1/Parkin mutations[227,228]. Explorations of this marker in biofluid samples will be of interest

16 possibly as confirmation of target engagement and longitudinally to assess progression rates of

17 disease in these PD subtypes. Similarly, the peroxisome proliferator-activated receptor γ

18 coactivator 1 alpha (PGC-1α) has been of interest due to its role as a regulator of mitochondrial

19 function[229]. The PGC-1α reference gene and PGC-1α levels are downregulated in human brain

20 and blood leukocytes in PD compared to control patients and this negatively correlates with

21 disease severity[230-232]. Interventions targeting mitochondrial processes might usefully measure

22 peripheral levels of PGC-1α.

23 A concern however for the use of mitochondrial blood-based biomarkers is that they do not

24 recapitulate *neuronal* mitochondrial dysfunction. Genetic mutations leading to mitochondrial

25 dysfunction in PD often show tissue-specific expression patterns and therefore peripheral blood

26 changes may lack interpretability[233,234]. This is supported by a recent study showing negligible

27 diagnostic value for well-established biomarkers of mitochondrial disease such as Fibroblast

28 growth factor 21 and Growth differentiation factor 15 in reflecting mitochondrial dysfunction in

29 PD patients[227].

30

Insulin resistance

The coexistence of Type 2 diabetes mellitus (T2DM) with PD results in more rapid motor and cognitive progression [235-238]. Faster progression appears to be independent from the existence of vascular disease in the brain [239] and at least in part explained by disruptions in physiological brain insulin signalling (central insulin resistance) [240] contributing to neurodegeneration [241].

Central insulin resistance can be measured through abnormalities in insulin signalling mediated by insulin-receptor substrate-1 (IRS-1). Tyrosine IRS-1 phosphorylation (IRS-1 p-Tyr) evokes insulin responsiveness, while serine phosphorylation primarily deactivates IRS-1 and attenuates insulin signalling [240,242]. Elevated IRS-1 phosphorylation at serine positions 616 (IRS-1 p-S616) and 312 (IRS-1 p-S312) represents attenuated insulin signalling [243,244] and has been noted in plasma EVs of PD patients [245,246]. Decreased IRS-1 p-Tyr distinguishes PD patients from HC and predicts cognitive impairment and motor severity [142]. Increases in EV IRS-1 p-Tyr were associated with motor benefits from exenatide in a clinical trial while increases in downstream p-Akt S473 predicted treatment response [245]. (Supplementary Table 1).

Peripheral insulin resistance as defined by a Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) value $\geq$ 2.0 or glycated hemoglobin (HbA1c) concentration $\geq$ 5.7%, occurs in up to 60% of PD patients [247]. The mechanistic importance of these finding in PD remains unclear as the HOMA-IR is not associated with cognition or motor symptoms [248,249]. Abnormal range HbA1C levels however predict motor and cognitive severity and progression in PD, while also being associated with the degree of axonal damage [250-253]. Further exploration of insulin resistance and/or body mass index in the selection of patients for trials of agents that mechanistically target this pathway is clearly of potential importance, while measurement of central insulin resistance using exosome IRS-1 p-Tyr may turn out to be of utility in confirming target engagement for a growing number of agents currently being studied for disease modification [254].

Synaptic degeneration

Disruptions to vesicle-mediated trafficking and secretory pathways with downstream effects on neurotransmitter levels and signalling as well as synaptic plasticity, are key features of synucleinopathies[255]. Proteins at different levels of this process have been explored for biomarker use (Table 2). Evidence to date suggests limited usefulness in PD, in part due to the confounding effect of dopaminergic therapies. Despite some studies suggesting alterations in serum and CSF levels of synaptic dopamine potentiators (β-Synuclein and growth associated protein 43 (GAP-43)) [255-261] and markers of synaptic plasticity (neurogranin (Ng), Contactin-1 (CNTN-1) and the zinc transporter ZnT3) in PD, inconsistencies between studies and poor correlation with motor severity and cognitive progression make future utility unlikely [260,262-269].

CSF concentrations of the secretory granule proteins (VGF and secretogranin-2) and the dense core vesicle protein prodynorphin are potentially useful in distinguishing PD from DLB or predicting cognitive decline[270,271]. Similarly, preliminary studies suggest CSF levels of the excitatory-inhibitory regulatory protein, Neuronal pentraxin-2 (NPTX2)[271] and the glutamate receptor GluA3[263] suggest value in reflecting cognitive status and distinguishing PD from DLB[272] and thus warrant further exploration in the assessment of cognitive progression.

Measuring panels of CSF protein levels reflecting neurotransmitter secretion, synaptic plasticity and autophagy will likely shape any future use of these markers[273]. An example of this approach includes combining CSF and serum EV levels of the principal components of the soluble N-ethylmaleimide sensitive factor attachment protein (SNARE) complex (synaptosomal-associated protein 25 (SNAP-25), the syntaxins 1A and 1B, syntaxin-binding protein-1, and the vesicle-associated membrane proteins (VAMP-1, VAMP-2)) with oligomeric α-synuclein to improve diagnostic accuracy [264,274]. Similarly, combining CSF Ng, NPTX2, total α-synuclein, and age [275] or CNTN-1, total α-synuclein, total tau, phosphorylated tau, and Aβ1-42[262]) can also improve diagnostic distinction.

A similar approach would also be worthwhile when considering the use of neurotransmitter metabolites. Despite decreased CSF levels of the dopamine metabolite homovanillic acid (HVA) being consistently noted in PD [276-281], repeated measurements in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study did not suggest usefulness for monitoring progression. Simultaneous metabolite panel measurement of dopaminergic (eg, 3,4-dihydroxyphenylalanine [DOPA], dopamine, 3,4-dihydroxyphenylacetic acid [DOPAC]),

noradrenergic (eg, 3,4-dihydroxyphenylglycol, 4-hydroxy-3-methoxyphenylglycol) and serotonergic (eg, 5-hydroxy-3-indoleacetic acid [5-HIAA]) metabolites in CSF[280] however correlates better with motor severity and DaT-SPECT uptake[282,283] and utility of the panel as a progression marker needs to be further explored.

Axonal damage

Neuro-axonal damage represents the end event of the pathophysiology of PD. Axon cytoskeletons are comprised of neurofilaments, structural proteins which allow for growth with large, myelinated axons having the highest content [284]. Neurofilament subunits are released upon axonal injury irrespective of the cause [284]. The neurofilament light chain (NfL) subunit is of diagnostic value in degenerative parkinsonian syndromes [285] while also correlating with nigrostriatal degeneration and greater reductions in presynaptic putaminal dopamine transporter (DAT) ratios over time [286 287]. This said, CSF NfL concentration does not seem to be increased in early PD [288] and significant increases are more indicative of atypical diagnoses rather than PD [288-291].

Blood NfL strongly correlates with CSF NfL [292-294] and reflects neurodegeneration in PD [294-297]. Although NfL levels were not elevated in a meta-analysis considering all patients with PD[293] and in one study exploring EV NFL levels[298], levels seem to be higher in more advanced PD [292,294,296,299] and the more severe PIGD-subtype [300,301]. Consistent inverse associations with cognitive scores have been reported [47,295-297,302-305] while NfL levels also predict more severe motor progression [287], cognitive decline [301,306] and progression to milestones (walking-aid, nursing-home living, reaching final Hoehn and Yahr (HY) stage 5 or death). Blood NfL may therefore be useful for trial stratification although its potential use as a surrogate endpoint might depend on the disease stage of recruited participants and trial duration [299,307].

The highest yield when using NfL seems to lie in combining it with clinical and disease specific fluid biomarkers. Examples of this include the ratio of NfL to Aβ42 in CSF, discriminating PD from PSP with good accuracy (AUC 0.93, sensitivity 89%, specificity 93%) [308] as well as the

use of a stepwise approach of firstly distinguishing synucleinopathies from non-synucleinopathies with skin α-syn SAA and then further distinguishing MSA from PD with NfL[309] or by combining CSF NfL, CSF α-synuclein SAA and brainstem imaging[310]. Similarly, PD progression is better predicted when combining markers with serum NfL, genetic status (ApoE4 and GBA) and validated prognostic clinical variables (age, verbal fluency, UPDRS axial scores) predicting unfavourable progression better than individual markers [311].

Imaging biomarkers

A range of imaging modalities have been explored for their biomarker potential. These include sonographic measurement of nigral signal, imaging approaches that measure brain structure, spectroscopy to explore brain biochemical changes, functional imaging to measure connectivity changes and radionuclide imaging to assess pre-synaptic and post synaptic dopaminergic and non-dopaminergic integrity as well as metabolic functional changes. (Box 2) Each approach has its strengths and weaknesses and potential biomarker roles in trials will depend on the stage of disease being studied as well as practical considerations of availability and effect strengths alongside and in comparison with, fluid biomarkers.

In the proposed staging system for PD, the development of dopaminergic dysfunction has been incorporated as an important staging threshold[12]. The range of imaging approaches that could be used for this are variable in their ability to discriminate PD from other pathophysiological processes as well as their potential for measuring the rate of progression of PD.

Transcranial Sonographic Imaging

Increased Substantia Nigra (SN) echogenicity likely due to accumulation of nigral iron is observed in PD [312-314] though a proportion of healthy controls and Essential Tremor patients also exhibit this [315]. This sign can however differentiate PD from PSP and MSA with good sensitivity (91%) and specificity (82–96%) [312]. Hyper-echogenicity remains unchanged over follow-up [316]

1 and does not correlate with disease severity [314,317] or presynaptic DAT loss [318] thus limiting use

2 as a progression marker.

3

Structural MRI techniques

5 Structural MRI approaches comprise; T1-weighted structural imaging methods which measure

6 cortical and subcortical volumetric changes and brain atrophy; neuromelanin-sensitive T1-

7 weighted imaging which is sensitive to measuring neuromelanin-iron complexes; iron-sensitive

8 MRI which captures iron deposition and dopaminergic cell loss; and diffusion imaging using

9 either single-tensor or 2-compartment diffusion modelling (free-water) which reflects

10 neurodegeneration and/or neuroinflammation.

11

T1-Weighted Structural MRI

13 T1-based structural MRI methods comprise; cortical thickness measurement, voxel-based

14 morphometry (VBM) and Deformation-based morphometry (DBM). Differences of these

15 approaches are summarised in Box 2.

16

17 Structural differences in the midbrain, putamen, brainstem, and cerebellum can distinguish PD

18 from atypical parkinsonian disorders[319]. This distinction is however best made in later disease

19 stages, at a time when disease modification approaches may be hardest to achieve. Novel

20 automated indexes may improve this though will need to be tested in independent cohorts[320].

21

22 In the PPMI cohort, deformation-based morphometry detected a unique atrophy pattern which

23 predicted motor progression in early PD without dementia [321]. A faster decline in prefrontal and

24 cingulate cortices and the caudate and thalamus has also been seen in de novo PD compared to

25 controls[322] while greater frontal atrophy after 18 months has also been noted in PD patients

26 without cognitive impairment with a disease duration of only 2 years [323] (though these findings

27 were separately contradicted [324]).

Studies in individuals with moderate to late-stage PD without dementia have also varied. No VBM differences were noted in one study [325] while another found reduced grey matter in the frontal lobe [326]. Longitudinal atrophy of occipital and fusiform regions has been noted in patients with a disease duration of over 5 years without cognitive impairment, while patients with cognitive impairment develop greater and more widespread atrophy in supplementary motor area, temporal, parietal, and occipital cortices [327]. Accelerated loss of gyrification in bilateral frontal and parietal regions in patients with a disease duration greater than 5 years compared to less than 5 years has also been noted [328].

In summary, T1-weighted structural MRI methods are sensitive to neurodegenerative progression even in the absence of cognitive impairment though this also seems to be better in more advanced disease stages. Replication studies demonstrating patterns of atrophy progression depending on disease stages are however currently lacking and will be important before recommendation for trial use. Furthermore, ascertaining the precise role of ultra-high-field scanners (7 T and above) which can provide sub millimetric anatomical information and higher degrees of diagnostic detail compared with 3 T MRI [329] will be important. Planned future longitudinal studies will be critical for informing this [330].

Neuromelanin & Iron sensitive imaging

Neuromelanin imaging (NMI) demonstrates only moderate sensitivity and specificity for distinguishing PD from healthy controls [331-335] while signal differences are also suboptimal for distinguishing atypical parkinsonian conditions from PD[336,337]. In contrast however, NMI shows reduced signal across disease stages (disease duration of 1.5 to 10 years) with a ventrolateral to anteromedial Substantia nigra (SN) progression pattern consistent with the neuropathological patterns of cell loss.

Iron-sensitive techniques including R2* relaxation imaging, susceptibility- weighted imaging (SWI), and quantitative susceptibility mapping (QSM) have similar ability to quantify nigral iron

deposition as NMI [338-340]. The absence of dorsal nigral hyperintensity corresponding to the region of nigrosome-1 (DNH) on iron-sensitive sequences distinguishes PD from controls well [329,341,342] regardless of disease duration [343]. Use for distinguishing atypical disorders from PD is however lacking while progression marker use seems to be disease duration dependent.

Although striatal, nigral, globus pallidus and caudate R2* relaxation rate increased in 2 separate studies after 2-years in early-stage PD [339,344], separate studies exploring R2* or QSM in de-novo patients [340] and patients with a disease duration < 1 year showed no longitudinal changes [343]. The use of R2* as a progression marker becomes clearer however in later disease stages[343] with increased relaxation time in SN R2* mapping over 3 years correlating with motor severity in cases with an initial disease duration of 5 years [345] while faster progression in the SN pars compacta seems to occur after a disease duration > 5 years [343].

Taken together, NMI and iron-sensitive imaging could potentially be usefully developed as progression biomarkers though values will need to be considered in the context of disease duration. Obviously, the use of iron-sensitive modalities will be particularly advantageous in trials targeting iron.

Diffusion imaging

Although some studies have demonstrated reduced SN fractional anisotropy with single tensor diffusion imaging in early PD [346-348] this was not confirmed by a meta-analysis of 10 studies [349]. Evidence in later disease (disease duration 10 years) is limited to one study demonstrating more anterior and rostral SN involvement [348]. On balance, this approach cannot currently be recommended for progression marker use. The finding of diffusion abnormality of the nucleus basalis of Meynert predicting development of cognitive impairment could be explored for balancing arms in small trials or selecting phenotypes that are likely to respond to specific treatments though replication of this finding is important [350].

Free water imaging studies have been more consistent with increased signal in the posterior SN being noted in early PD [351,352]. Free water in the posterior SN also increases over 4 years and change over 1 year can predict H&Y 4-year change [352]. This increase continues in later disease stages (duration over 7 years) where longitudinal increases in free water occurs in the anterior but not posterior SN [353]. This modality is promising as a progression biomarker though may require selecting the region of interest depending on disease stage. Free-water imaging of the basal ganglia, midbrain, and cerebellum and the application of automated Imaging Differentiation is promising for differentiating PD from atypical conditions [354]. This approach was found to be superior to a conventional Magnetic Resonance Parkinsonism Index as well as plasma NfL levels for distinguishing PD from atypical conditions[355].

Proton Magnetic Resonance Spectroscopy

Proton magnetic resonance spectroscopy (MRS) reveals the metabolic status of the region sampled for a specific disease process. In PD, N-acetyl aspartate/creatine (NAA/Cr) ratios in the SN are reduced compared to controls and correlate with disease severity [356,357]. Lower ratios have also been noted in the lentiform nucleus (LN), temporoparietal and posterior cingulate cortices, as well as the pre-supplementary motor area [358-361] though correlation with disease severity is less clear [359,360]. NAA/Cr ratios are lower in the rostral SN in PD with an inverted pattern in atypical parkinsonian patients and HC [362]. Taken together, there is some preliminary level of evidence that MRS could serve to improve PD diagnostics though may be best used in combination with conventional MRI by increasing specificity.

Phosphorus based magnetic resonance spectroscopy (31P-MRS) has been of specific interest for a subset of potential interventions as it can assess mitochondrial function. In vivo Pi/ATP and PCr/ATP ratios reflect oxidative phosphorylation pathways [363]. Reductions in ATP and PCr [364] and increased Pi/ATP ratios [365] in the putamen and midbrain of PD patients compared to controls have been reported while differences can also distinguish PD from PSP (AUC 0.93)[366]. Longitudinal ratio improvement suggestive of target engagement was also noted in a recently completed disease modifying trial of ursodeoxycholic acid[367].

1

Functional MRI

3 Resting-state and task-based functional MRI reveal networks involved in motor, cognitive, and
4 affective processes. Network impairments have been associated with motor and non-motor
5 symptoms. Reduced resting-state connectivity between the striatum and thalamus, midbrain,
6 pons and cerebellum has been noted in PD as have connectivity changes between cortical and
7 subcortical areas [368]. Reduced resting-state functional connectivity within the basal ganglia
8 network can differentiate PD from HC (sensitivity 100%, specificity 89.5%) [369] while cerebellar
9 connectivity with multiple brain networks differs between PD and MSA [370]. Longitudinal task-
10 based functional MRI can track progression with declining activity in the putamen and primary
11 motor cortex over 1 year [371] though the impact of levodopa administration on network
12 connectivity is an important consideration [372]. Although available evidence for this modality is
13 overall promising, more widespread replication of diagnostic and progression findings are
14 necessary.

15

PET/SPECT imaging

Radionuclide imaging

18 Several radiolabelled probes for imaging α-synuclein have been explored though no tracer is
19 currently of diagnostic value for PD. Issues to overcome include developing tracers for
20 intracellular targeting with ideal lipophilicity, and tracer selectivity for α-synuclein over amyloid
21 and tau aggregates [373,374]. More recently however, a newly developed α-synuclein Positron
22 Emission Tomography (PET) tracer, [18F] ACI-12589 was shown to bind to basal ganglia and
23 cerebellar white matter in a small cohort though this was confined to MSA patients[375]. Larger
24 studies examining diagnostic accuracy for distinguishing PD from MSA will be critical.

25

Dopaminergic tracers

27 A variety of radionuclide tracers are available to examine pre- and post-synaptic striatal
28 dopaminergic function using Positron emission tomography (PET) or single photon emission

1 tomography (SPECT) imaging. At the presynaptic level, molecular targets and their respective

2 tracers include L-aromatic amino acid decarboxylase (AADC/tracer F-DOPA), vesicular

3 monoamine transporter 2 (VMAT2/tracer [11C]-dihydrotetrabenazine) and the dopamine

4 transporter (DAT/tracers CFT PET and 123I-CIT SPECT) density.

5

6 These markers are sensitive for the detection of dysfunction or loss of striatal dopaminergic

7 terminals and enable the identification of parkinsonian syndromes with nigral neurodegeneration

8 though do not reliably distinguish PD from atypical disorders. Visually assessing for the

9 presence of nigrostriatal degeneration with this modality is increasingly used in trial

10 recruitment[376] to exclude patients with clinical presentations in keeping with PD but with scans

11 without evidence of dopaminergic deficit (SWEDDS) due to e.g. drug induced parkinsonism[377-

12 379]. Objective measurement of striatal uptake in comparison to other regions may however be

13 more useful in trials recruiting patients with more established PD as these ratios can reflect

14 motor and non-motor disease severity as well as progression through disease stages although

15 hemispheric dominance and type of tracer used are important considerations[380]. Striatal

16 dopaminergic markers decline most prominently in the first years of motor disease before largely

17 plateauing within 5 years of diagnosis[381-384]. Quantification of dopaminergic markers in the

18 midbrain/SN may be better markers beyond this point [385].

19

20 The type of dopaminergic tracer used can potentially be critical for tracking progression in trials

21 and measuring treatment response with VMAT2 imaging is less subject to compensatory changes

22 in expression than DAT and F-DOPA[386]. Quantitative dopaminergic assessments have been used

23 in a number of recent disease modification trials though with overall negative findings to date.

24 (Supplementary table 1)

25 Dopamine receptor expression can also be estimated at the postsynaptic level with PET ligands

26 such as [^{11}C]-raclopride, [^{18}F]-fallypride or ^{123}I-IBZM SPECT (all of which bind to D2

27 receptors) or agents such as [^{11}C]NNC 112 which binds to D(1) receptors[387]. Preservation of

28 post-synaptic dopamine receptors is typical of PD whereas post synaptic receptor loss early in

29 the disease is more likely indicative of an atypical form of parkinsonism. Imaging results depend

30 on the dose and timing of oral dopamjnergic replacement and the usefulness of this type of

imaging approach may perhaps be restricted to restorative approaches such as cell or gene therapy interventions[388].

Non-dopaminergic tracers

Radionuclide imaging studies of the serotonergic and cholinergic systems demonstrate associations with non-motor PD pathophysiology. Reduced binding on serotonergic imaging has been noted in individuals with early PD (disease duration less than 5 years) [389]. Serotonergic denervation also correlates with increased dopamine turnover and reduced levodopa responses [390]. In later disease stages (disease duration 5 to 10 or more years), serotonergic transporter binding remains reduced compared to controls [389] and the degree of serotonergic pathology is associated with cognitive decline [391]. Cholinergic denervation also occurs in early PD (disease duration less than 3 years) but is more pronounced in PD with dementia [392]. Noradrenergic activity, quantifiable by PET imaging is reduced in PD and is associated with the presence of RBD and cognitive impairment [393]. The utility of these markers in tracking progression is of interest but not yet sufficiently clear.

Synaptic density

Synaptic density quantification irrespective of neurotransmitter type has also been of interest in PD. Tracers quantifying the concentration of the synaptic vesicle 2A protein (18F-UCB-H or 11C-UCB-J) reflect this and have been studied in several cohorts. Lower binding potential in both cortical and sub-cortical regions have been noted in PD though this is most prominent in the SN[394]. Correlation with clinical status has however been inconsistent though one study suggested more prominent and extensive reductions in PD dementia and DLB cases[395-397]. Similarly, small cohort studies using 11C-UCB-J PET did not note binding changes over 2 years[395,398]. Current evidence therefore does not support the use of this marker in clinical trials.

Metabolic and network imaging

Glucose metabolism

^{18}F-FDG-PET parieto-occipital hypometabolism is noted in PD [399,400] while preserved glucose metabolism in the basal ganglia distinguishes PD from MSA and PSP [399]. Inferior parietal and left caudate glucose hypometabolism in PD, also correlates with motor and cognitive deficits [401]. A unique PD-related pattern (PDRP) characterised by elevated pallidothalamic and pontine metabolic activity with reduction in the supplementary motor area, premotor cortex, and parietal association areas has also been noted in cases prior to dopaminergic treatment [402] and can differentiate PD from atypical parkinsonism [403].

PDRP progresses in early PD (disease duration less than 2 years) over 24 months, suggesting potential progression marker use in the early stages [404] though a critical limitation is that acute dopaminergic treatment diminishes the pattern [405]. A PD-related cognitive pattern (PDCP) characterised by a reduction in the medial frontal and parietal association regions, and metabolic increase in cerebellar cortex and dentate nuclei [406] has also been described. This pattern seems to occur years after the PDRP [404,407], increases over time [404] and is higher in those with dementia [408]. The PDCP also correlates with memory and executive performance [406] while its lack of change with dopaminergic treatment potentially supports its use as a marker of cognitive dysfunction [409]. These separate metabolic networks could potentially be used to track progression and treatment response in the appropriate setting.

Neuroinflammation imaging

The PET ligands 11C-PK11195, 11C-PBR28 and 18F-FEPPA which bind to the 18 kDa translocator protein (TSPO) on mitochondria in microglia have been used for imaging neuroinflammation with TSPO upregulation suggesting microglial activation [410].

PD clinical severity and putaminal presynaptic dopaminergic integrity correlates with ^{11}C-PK11195 binding [411]. Binding affinity can vary with TPSO genetic polymorphisms which needs appropriate adjustment in analyses[410,412]. Taken alone, TPSO patterns lack the ability to distinguish parkinsonian conditions though their future use may be as biomarkers of therapeutic response for interventions targeting neuroinflammation [413].

Limitations of biomarkers

A framework for considering the definition of PD according to the presence /absence of α-syn SAA-CSF is potentially a major step forward in planning PD trials. Several practical obstacles need to be considered however prior to the routine use/reliance on biomarkers in the clinical trial context. Firstly, acquiring some biomarkers e.g. CSF requires an invasive procedure which may be unacceptable for some participants. Growing evidence of the equivalence of α-syn SAA-in skin to that seen with CSF could however overcome this limitation. The demonstration of equivalence of testing on even less invasive samples such as serum/plasma or within peripherally obtained EVs is therefore a priority. With greater demonstration of validity, routine testing of peripherally acquired biomarkers can become normal practice, for example the widespread availability of plasma NfL testing in healthcare laboratories.

Interpretation of discrepant results between studies attributable to preanalytical and analytical confounders, different techniques employed and a lack of factoring of different protein species measured (total α-synuclein vs oligomeric) needs careful critique. Similarly, imaging studies are affected by methodological discrepancies including different assumptions for correction of serial data as well as sample size, power, and study design caveats and the use of different outcome measures. Collaborative studies allowing analysis of larger sample sizes with adequate follow-up that employ standardized sampling and analysis methodology will improve these limitations, as demonstrated by the harmonisation of large numbers of samples processed in PPMI.

The major limitation in biomarker discovery is undoubtedly difficulty with validation. Association between a change in a biological assay alongside a clinical state need not equal causation. For example, biological changes may represent healthy compensatory responses to a pathological process. Furthermore, even biomarkers that do reflect active processes of neurodegeneration may not have linear relationships over the course of disease particularly if production ultimately declines because of widespread tissue death. While it is possible to use clinico-pathological data for validation, confirmation that a biomarker predicts slowing of

disease progression necessarily requires the identification of an agent which achieves this according to our threshold whether that be clinical, patient reported, functional impairment or quality of life milestones which have inherent limitations.

To date, no single biomarker can yet be recommended to act as a surrogate for clinical disease progression in PD. Combinations of fluid biomarkers invariably increase the strength of their individual predictive properties. While fluid and imaging biomarkers are often collected from the same trial participants, explorations of the utility of multiple fluid biomarkers as a panel alongside imaging in combination, are rare. This approach was partly adopted in the recent deferiprone trial (Supplementary Table 1) where brain iron content using T2* sequences and plasma ferritin and prolactin levels were used as combined markers of target engagement and specific measures of treatment effect while structural imaging for measurement of brain atrophy and DAT-SPECT imaging was used to explore the impact of the agent on overall disease progression (atrophy and nigrostriatal degeneration). Although clinical worsening in the deferiprone treated group complicates interpretation of how well the panel of biomarkers performed, one could argue that they did reflect the effect of the drug with decreased nigrostriatal iron content and plasma ferritin and increased plasma prolactin in the deferiprone group, while no inverse correlation between brain-structure volumes and iron content was noted in keeping with the negative clinical findings over a relatively short duration of follow-up.

Challenges for future trials will be in the choice of selection of suitable combinations of fluid and imaging biomarkers that complement each other. This will certainly need to be strongly guided by the biological action of the agent being tested and the stage of the disease of their participants being treated, though those biomarkers that appear to most closely align with disease progression should be prioritised. How much weight each biomarker in the panel will ultimately carry will become more easily evident following a positive clinical trial.

Conclusions & Recommendations

The identification of a better framework for the certainty of a PD diagnosis based on positivity of α-syn SAA-CSF is a major step forwards, and less invasive equivalent alternatives will help even more. The further development of reliable biomarkers of PD neurodegeneration could further facilitate prognostication, identification of disease subtypes, conduct of clinical trials and identification of agents that may slow down or stop these processes. The precise role for biomarkers will depend on the mechanism of action of the agent in question, and the decision made regarding the stage of the illness at which the intervention is being applied. There is interest in recruiting people earlier in the neurodegenerative process, even prior to symptom onset, given that intuitively earlier intervention may provide a better chance of preventing irreversible cell death [414]. Alongside trials in prodromal cohorts, there will remain a need to identify whether any disease modifying intervention has an impact on the 6-10 million people already struggling with symptoms, and in need of prevention of further decline.

In this group, PD diagnosis is less difficult though a sizeable proportion of cases at this stage with atypical parkinsonian disorders can be mistaken as suffering from PD and therefore inadvertently recruited into disease modifying trials. While there will remain healthy debate whether α-synuclein oligomeric seeding and propagation is the primary cause of PD neurodegeneration, it appears that the α-syn SAA-CSF assay reflects an alpha synuclein related neurodegenerative process and can reliably distinguish synucleinopathies from other causes of parkinsonism/tremor with high specificity.

PD subtyping is also a high priority for better selection of responders. For example, interventions that specifically target an aspect of disease pathophysiology associated with genetic abnormalities could be specifically tailored to these patients [415]. Mutations in GBA1 confer a worse prognosis and therefore a trial enriched with these patients may potentially allow an earlier signal of efficacy. In parallel, enhancement of GCase activity may also have therapeutic benefits in PD patients without GBA1 mutations [416].

Features that strongly predict subsequent disease progression need to be carefully considered during treatment allocation. The randomisation process itself should lead to balancing of features between placebo and active treatment arms, however this can fail to achieve this in smaller sized trials. The application of a panel of biomarkers for example pro-inflammatory immune markers which predict faster progression [181] and reflect different aspects of disease-related pathways would be a useful approach to stratify patients into prognostic groups and potential responders to the treatment being tested which will in turn enable more efficient and cost-effective collection of data and increase the likelihood of detecting an effect.

The most useful function of biomarkers is in the prediction that a change in any such biomarker reliably predicts slowing down of the neurodegenerative process that translates to reduction in disability accrual, and maintenance of function and quality of life. Towards this, the ratio of phosphorylated or oligomeric α-synuclein to total α-synuclein in CSF appears to be an encouraging fluid biomarker for disease progression. Technical challenges notwithstanding, measurement of one or both of these ratios may become routine practice in clinical trials of disease modifying agents, to further improve diagnostic precision at baseline, minimise difference between trial arms and monitor changes in response to the intervention. The selection of a single fluid biomarker is likely to be a lower sensitivity surrogate for disease progression than the use of a panel of biomarkers. The development of a poly-biomarker, analogous to a polygenic risk score will require careful modelling in large cohorts that have collected identical panels using agreed standardised operating procedures for their collection.

There are several structural imaging techniques that seem to reliably track disease progression in PD, perhaps the most useful of which are neuromelanin or free water MRI. Whether these allow sufficient resolution to quantify changes over shorter time periods than needed for conventional clinical methods, requires further data. Functional or PET imaging may allow more rapid confirmation of target engagement in trials, and their routine use may depend on the putative mechanism of action of the intervention e.g. TSPO PET in a trial of a neuroinflammatory intervention. While stabilization of fluid, imaging or tissue biomarkers should mirror attenuation

1 of α-synuclein aggregation within the brain, it remains to be seen whether change in biomarker

2 activity can reliably predict subsequent clinical disease progression.

3

4 In terms of recommendations, during the design and conduct of a clinical trial of a disease

5 modifying intervention in PD, we suggest;

6   1. For broad interventions, investigators should routinely collect a biomarker (CSF, skin,

7   blood) that can be used for an α-syn SAA as part of the trial inclusion criteria. Currently,

8   SAA offers the highest specificity in distinguishing PD from controls or PD like

9   conditions but it's utility in differentiating PD from MSA requires further assay

10   refinement.

11   2. For precision interventions, investigators should consider whether the planned

12   intervention targets an alternative process that can be defined by an alternative genetic

13   marker (LRRK2, GBA1, Mitochondrial mutation), or measurable pathophysiological

14   process (neuroinflammation, bioenergetics), irrespective of α-syn SAA.

15   3. Investigators should consider incorporating such a biomarker within the trial inclusion

16   criteria, while also ensuring the biomarker is appropriate for the stage of disease being

17   studied.

18   4. Where appropriate, the same biomarker might also be used to confirm target engagement

19   of the intervention.

20   5. Clinical outcome analyses may need to incorporate baseline differences in panels of wet

21   biomarkers, as well as imaging differences between treatment groups predictive of more

22   rapid progression.

23   6. Investigators should formally evaluate the relationship between biomarker changes and

24   predicting the clinical effect of the intervention.

25   7. Consideration should be given at an early stage how biomarker data can be usefully

26   shared/integrated to maximise learning across interventions.

27 Until we have identified an agent that slows down clinical progression, it will be difficult to

28 conclude the validity of any biomarker at predicting such disease modification. It appears as a

somewhat circular argument therefore, that we need success, before we can be confident in our tools designed to help achieve success. Faced with this challenge, the most practical path forward is to systematically collect specimens from participants in clinical trials for future research while also incorporating longitudinal measurement of encouraging biomarkers for continued comparison with clinical progression measures. This requires a degree of consensus in the PD trials community regarding standardised protocols for specimen collection and analysis. The Critical Path for Parkinson's (CPP) consortium are helping to achieve this [417]. Differences in the longitudinal change in biomarkers according to candidate interventions will undoubtedly help in the understanding of target engagement and help in the eventual prediction of long-term outcomes, and ultimately are likely to become reliable surrogate outcome measures.

In conclusion, we should remain optimistic that the use of a combination of fluid, tissue and imaging biomarkers may become sufficient to reliably demonstrate disease modification. There is already a precedent that change in an imaging biomarker has been considered sufficient evidence, by some, to conclude disease modifying properties of aducanumab in Alzheimer's disease [418]. This decision has been controversial, and it is likely that a more robust conclusion in PD would only be reached once any combination of biomarkers has been comprehensively validated in relation to patient reports of clinical symptoms of relevance to their health and wellbeing. In the meantime, the best biomarker candidates can already likely improve the selection of participants and may contribute to early assessments of target engagement and of efficacy in counteracting pathophysiological mechanisms. An ongoing systematic process of confirming clinico-biomarker validity and utility is required.

Acknowledgements

Funding

Competing interests

The authors report no competing interests.

Supplementary material

Supplementary material is available at *Brain* online.

References

1.   Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T. Progress towards therapies for disease modification in Parkinson's disease. *Lancet Neurol*. Jul 2021;20(7):559-572. doi:10.1016/S1474-4422(21)00061-2

2.   Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther*. Mar 2001;69(3):89-95. doi:10.1067/mcp.2001.113989

3.   Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. *Prog Brain Res*. 2010;183:115-45. doi:10.1016/S0079-6123(10)83007-9

4.   Siderowf A, Concha-Marambio L, Lafontant DE, *et al*. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-

synuclein seed amplification: a cross-sectional study. *Lancet Neurol*. May 2023;22(5):407-417. doi:10.1016/S1474-4422(23)00109-6

5.   Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of Synucleinopathies. *Mol Neurodegener*. Dec 18 2021;16(1):83. doi:10.1186/s13024-021-00501-z

6.   Fenyi A, Leclair-Visonneau L, Clairembault T*, et al*. Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification. *Neurobiol Dis*. Sep 2019;129:38-43. doi:10.1016/j.nbd.2019.05.002

7.   Kang UJ, Boehme AK, Fairfoul G*, et al*. Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson's disease. *Mov Disord*. Apr 2019;34(4):536-544. doi:10.1002/mds.27646

8.   Manne S, Kondru N, Jin H*, et al*. Blinded RT-QuIC Analysis of alpha-Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients. *Mov Disord*. Dec 2020;35(12):2230-2239. doi:10.1002/mds.28242

9.   Rossi M, Candelise N, Baiardi S*, et al*. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. *Acta Neuropathol*. Jul 2020;140(1):49-62. doi:10.1007/s00401-020-02160-8

10.   Russo MJ, Orru CD, Concha-Marambio L*, et al*. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease. *Acta Neuropathol Commun*. Nov 6 2021;9(1):179. doi:10.1186/s40478-021-01282-8

11.   Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L. alpha-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward. *Neurology*. Aug 2 2022;99(5):195-205. doi:10.1212/WNL.0000000000200878

12.   Chahine LM, Merchant K, Siderowf A*, et al*. Proposal for a Biologic Staging System of Parkinson's Disease. *J Parkinsons Dis*. Apr 10 2023;doi:10.3233/JPD-225111

13.   Höglinger GU. Towards a Biological Definition of Parkinson's Disease. *Preprintsorg*. 2023;doi:10.20944/preprints202304.0108.v1

14.   Reinoso G, Allen JC, Jr., Au WL, Seah SH, Tay KY, Tan LC. Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study. *Eur J Neurol*. Mar 2015;22(3):457-63. doi:10.1111/ene.12476

15.   Papapetropoulos S. Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials. *Cns Neurosci Ther*. 2012;18(5):380-387. doi:10.1111/j.1755-5949.2011.00253.x

16.   Utsumi H, Terashi H, Ishimura Y, *et al*. How far do the complaints of patients with Parkinson's disease reflect motor fluctuation? Quantitative analysis using a portable gait rhythmogram. *ISRN Neurol*. 2012;2012:372030. doi:10.5402/2012/372030

17.   Davidson MB, McGhee DJ, Counsell CE. Comparison of patient rated treatment response with measured improvement in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. Oct 2012;83(10):1001-5. doi:10.1136/jnnp-2012-302741

18.   Parashos SA, Luo S, Biglan KM, *et al*. Measuring Disease Progression in Early Parkinson Disease The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. *Jama Neurology*. Jun 2014;71(6):710-716. doi:10.1001/jamaneurol.2014.391

19.   McGhee D, Parker A, Fielding S, Counsell C. Which Clinical Measures Are Most Appropriate for Measuring Disease Progression in Parkinson's Disease? *J Neurol Neurosur Ps*. Nov 2013;84(11)doi:10.1136/jnnp-2013-306573.163

20.   Hong Z, Shi M, Chung KA, *et al*. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. *Brain*. Mar 2010;133(Pt 3):713-26. doi:10.1093/brain/awq008

21.   Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. *Lancet Neurol*. Mar 2011;10(3):230-40. doi:10.1016/S1474-4422(11)70014-X

22.   Mollenhauer B, Trautmann E, Taylor P, *et al*. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. *Neurosci Lett*. Jan 4 2013;532:44-8. doi:10.1016/j.neulet.2012.11.004

23. Tokuda T, Salem SA, Allsop D, *et al.* Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. *Biochem Biophys Res Commun*. Oct 13 2006;349(1):162-6. doi:10.1016/j.bbrc.2006.08.024

24. Eusebi P, Giannandrea D, Biscetti L, *et al.* Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease: A systematic review and meta-analysis. *Mov Disord*. Oct 2017;32(10):1389-1400. doi:10.1002/mds.27110

25. Gao L, Tang H, Nie K, *et al.* Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. *Int J Neurosci*. 2015;125(9):645-54. doi:10.3109/00207454.2014.961454

26. Sako W, Murakami N, Izumi Y, Kaji R. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. *Mov Disord*. Nov 2014;29(13):1599-605. doi:10.1002/mds.26036

27. Zhou B, Wen M, Yu WF, Zhang CL, Jiao L. The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid alpha -Synuclein Levels in Parkinson's Disease: A Meta-Analysis. *Parkinsons Dis*. 2015;2015:567386. doi:10.1155/2015/567386

28. De Bartolo MI, Vivacqua G, Belvisi D, *et al.* A Combined Panel of Salivary Biomarkers in de novo Parkinson's Disease. *Annals of Neurology*. Mar 2023;93(3):446-459. doi:10.1002/ana.26550

29. Chahine LM, Beach TG, Brumm MC, *et al.* In vivo distribution of alpha-synuclein in multiple tissues and biofluids in Parkinson disease. *Neurology*. Sep 1 2020;95(9):e1267-e1284. doi:10.1212/WNL.0000000000010404

30. Stuendl A, Kunadt M, Kruse N, *et al.* Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. *Brain*. Feb 2016;139(Pt 2):481-94. doi:10.1093/brain/awv346

31. Shi M, Liu C, Cook TJ, *et al.* Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease. *Acta Neuropath*. Nov 2014;128(5):639-650. doi:10.1007/s00401-014-1314-y

32. Stuendl A, Kraus T, Chatterjee M, *et al*. alpha-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. *Mov Disord*. Nov 2021;36(11):2508-2518. doi:10.1002/mds.28639

33. Zhao ZH, Chen ZT, Zhou RL, Zhang X, Ye QY, Wang YZ. Increased DJ-1 and alpha-Synuclein in Plasma Neural-Derived Exosomes as Potential Markers for Parkinson's Disease. *Front Aging Neurosci*. 2018;10:438. doi:10.3389/fnagi.2018.00438

34. Niu M, Li Y, Li G, *et al*. A longitudinal study on alpha-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression. *Eur J Neurol*. Jun 2020;27(6):967-974. doi:10.1111/ene.14208

35. Jiang C, Hopfner F, Katsikoudi A, *et al*. Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism. *J Neurol Neurosurg Psychiatry*. Jul 2020;91(7):720-729. doi:10.1136/jnnp-2019-322588

36. Fu Y, Jiang C, Tofaris GK, Davis JJ. Facile Impedimetric Analysis of Neuronal Exosome Markers in Parkinson's Disease Diagnostics. *Anal Chem*. Oct 20 2020;92(20):13647-13651. doi:10.1021/acs.analchem.0c03092

37. Dutta S, Hornung S, Kruayatidee A, *et al*. alpha-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy. *Acta Neuropathol*. Sep 2021;142(3):495-511. doi:10.1007/s00401-021-02324-0

38. Si X, Tian J, Chen Y, Yan Y, Pu J, Zhang B. Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease. *Neuroscience*. Aug 10 2019;413:308-316. doi:10.1016/j.neuroscience.2019.05.015

39. Cao Z, Wu Y, Liu G, *et al*. alpha-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease. *Neurosci Lett*. Mar 23 2019;696:114-120. doi:10.1016/j.neulet.2018.12.030

40. Zhao Y, Yang GF. Potential of extracellular vesicles in the Parkinson's disease-Pathological mediators and biomarkers. *Neurochem Int*. Mar 2021;144doi:ARTN 104974 10.1016/j.neuint.2021.104974

41.   Ohmichi T, Mitsuhashi M, Tatebe H, Kasai T, El-Agnaf OMA, Tokuda T. Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases. *Parkinsonism Relat D*. Apr 2019;61:82-87. doi:10.1016/j.parkreldis.2018.11.021

42.   Xylaki M, Chopra A, Weber S, Bartl M, Outeiro TF, Mollenhauer B. Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis. *Mov Disord*. Jul 14 2023;doi:10.1002/mds.29497

43.   Jiang C, Hopfner F, Berg D*, et al*. Validation of alpha-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes. *Mov Disord*. Nov 2021;36(11):2663-2669. doi:10.1002/mds.28591

44.   Wang Y, Shi M, Chung KA*, et al*. Phosphorylated alpha-synuclein in Parkinson's disease. *Sci Transl Med*. Feb 15 2012;4(121):121ra20. doi:10.1126/scitranslmed.3002566

45.   Stewart T, Sossi V, Aasly JO*, et al*. Phosphorylated alpha-synuclein in Parkinson's disease: correlation depends on disease severity. *Acta Neuropathol Commun*. Jan 31 2015;3:7. doi:10.1186/s40478-015-0185-3

46.   Majbour NK, Vaikath NN, van Dijk KD*, et al*. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. *Mol Neurodegener*. Jan 19 2016;11:7. doi:10.1186/s13024-016-0072-9

47.   Oosterveld LP, Verberk IMW, Majbour NK*, et al*. CSF or serum neurofilament light added to alpha-Synuclein panel discriminates Parkinson's from controls. *Mov Disord*. Feb 2020;35(2):288-295. doi:10.1002/mds.27897

48.   Parnetti L, Gaetani L, Eusebi P*, et al*. CSF and blood biomarkers for Parkinson's disease. *Lancet Neurol*. Jun 2019;18(6):573-586. doi:10.1016/S1474-4422(19)30024-9

49.   Cariulo C, Martufi P, Verani M*, et al*. Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay. *Front Neurosci*. 2019;13:889. doi:10.3389/fnins.2019.00889

50.   Foulds PG, Mitchell JD, Parker A*, et al*. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. *FASEB J*. Dec 2011;25(12):4127-37. doi:10.1096/fj.10-179192

51.   Foulds PG, Diggle P, Mitchell JD, *et al*. A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson's disease. *Sci Rep*. 2013;3:2540. doi:10.1038/srep02540

52.   Foulds PG, Yokota O, Thurston A, *et al*. Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. *Neurobiol Dis*. Jan 2012;45(1):188-95. doi:10.1016/j.nbd.2011.08.003

53.   Majbour NK, Aasly JO, Hustad E, *et al*. CSF total and oligomeric alpha-Synuclein along with TNF-alpha as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers. *Transl Neurodegener*. May 6 2020;9(1):15. doi:10.1186/s40035-020-00192-4

54.   van Steenoven I, Majbour NK, Vaikath NN, *et al*. alpha-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. *Mov Disord*. Nov 2018;33(11):1724-1733. doi:10.1002/mds.111

55.   Schulz I, Kruse N, Gera RG, *et al*. Systematic Assessment of 10 Biomarker Candidates Focusing on alpha-Synuclein-Related Disorders. *Mov Disord*. Dec 2021;36(12):2874-2887. doi:10.1002/mds.28738

56.   Ikemura M, Saito Y, Sengoku R, *et al*. Lewy body pathology involves cutaneous nerves. *J Neuropathol Exp Neurol*. Oct 2008;67(10):945-53. doi:10.1097/NEN.0b013e318186de48

57.   Wang N, Gibbons CH, Lafo J, Freeman R. alpha-Synuclein in cutaneous autonomic nerves. *Neurology*. Oct 29 2013;81(18):1604-10. doi:10.1212/WNL.0b013e3182a9f449

58.   Wang N, Garcia J, Freeman R, Gibbons CH. Phosphorylated Alpha-Synuclein Within Cutaneous Autonomic Nerves of Patients With Parkinson's Disease: The Implications of Sample Thickness on Results. *J Histochem Cytochem*. Oct 2020;68(10):669-678. doi:10.1369/0022155420960250

59.   Liu X, Yang J, Yuan Y, *et al*. Optimization of the Detection Method for Phosphorylated alpha-Synuclein in Parkinson Disease by Skin Biopsy. *Front Neurol*. 2020;11:569446. doi:10.3389/fneur.2020.569446

60.   Donadio V, Incensi A, El-Agnaf O, *et al*. Skin alpha-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study. *Sci Rep*. Sep 24 2018;8(1):14246. doi:10.1038/s41598-018-32588-8

61.   Gibbons C, Wang N, Rajan S, *et al*. Cutaneous alpha-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease. *Neurology*. Jan 19 2023;doi:10.1212/WNL.0000000000206772

62.   Donadio V, Incensi A, Rizzo G, *et al*. Skin Biopsy May Help to Distinguish Multiple System Atrophy-Parkinsonism from Parkinson's Disease with Orthostatic Hypotension. *Movement Disord*. Sep 2020;35(9):1649-1657. doi:10.1002/mds.28126

63.   Kang W, Chen W, Yang Q, *et al*. Salivary total alpha-synuclein, oligomeric alpha-synuclein and SNCA variants in Parkinson's disease patients. *Sci Rep*. Jun 23 2016;6:28143. doi:10.1038/srep28143

64.   Tokuda T, Qureshi MM, Ardah MT, *et al*. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. *Neurology*. Nov 16 2010;75(20):1766-72. doi:10.1212/WNL.0b013e3181fd613b

65.   Hansson O, Hall S, Ohrfelt A, *et al*. Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. *Alzheimers Res Ther*. 2014;6(3):25. doi:10.1186/alzrt255

66.   Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. *J Clin Neurol*. Dec 2011;7(4):215-22. doi:10.3988/jcn.2011.7.4.215

67.   Parnetti L, Farotti L, Eusebi P, *et al*. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's Disease. *Front Aging Neurosci*. 2014;6:53. doi:10.3389/fnagi.2014.00053

68.   El-Agnaf OM, Salem SA, Paleologou KE, *et al*. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. *FASEB J*. Mar 2006;20(3):419-25. doi:10.1096/fj.03-1449com

69.   Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. *Mov Disord*. Mar 15 2010;25(4):489-93. doi:10.1002/mds.22928

70. Papagiannakis N, Koros C, Stamelou M, *et al*. Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease. *Neurosci Lett*. Apr 13 2018;672:145-149. doi:10.1016/j.neulet.2017.11.012

71. Daniele S, Frosini D, Pietrobono D, *et al*. alpha-Synuclein Heterocomplexes with beta-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity. *Front Mol Neurosci*. 2018;11:53. doi:10.3389/fnmol.2018.00053

72. Vivacqua G, Latorre A, Suppa A, *et al*. Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease. *PLoS One*. 2016;11(3):e0151156. doi:10.1371/journal.pone.0151156

73. Vivacqua G, Suppa A, Mancinelli R, *et al*. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. *Parkinsonism Relat Disord*. Jun 2019;63:143-148. doi:10.1016/j.parkreldis.2019.02.014

74. Devic I, Hwang H, Edgar JS, *et al*. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. *Brain*. Jul 2011;134(Pt 7):e178. doi:10.1093/brain/awr015

75. Kharel S, Ojha R, Bist A, Joshi SP, Rauniyar R, Yadav JK. Salivary alpha-synuclein as a potential fluid biomarker in Parkinson's disease: A systematic review and meta-analysis. *Aging Med (Milton)*. Mar 2022;5(1):53-62. doi:10.1002/agm2.12192

76. Hamm-Alvarez SF, Okamoto CT, Janga SR, *et al*. Oligomeric alpha-synuclein is increased in basal tears of Parkinson's patients. *Biomark Med*. Aug 2019;13(11):941-952. doi:10.2217/bmm-2019-0167

77. Maass F, Rikker S, Dambeck V, *et al*. Increased alpha-synuclein tear fluid levels in patients with Parkinson's disease. *Sci Rep*. May 22 2020;10(1):8507. doi:10.1038/s41598-020-65503-1

78. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA. alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. *PLoS One*. Apr 25 2011;6(4):e18513. doi:10.1371/journal.pone.0018513

79. Wang X, Yu S, Li F, Feng T. Detection of alpha-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease. *Neurosci Lett*. Jul 10 2015;599:115-9. doi:10.1016/j.neulet.2015.05.030

80.   Meloni M, Agliardi C, Guerini FR, *et al.* Oligomeric alpha-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms. *Neurobiol Dis*. Jan 2023;176:105947. doi:10.1016/j.nbd.2022.105947

81.   Schweighauser M, Shi Y, Tarutani A, *et al.* Structures of alpha-synuclein filaments from multiple system atrophy. *Nature*. Sep 2020;585(7825):464-469. doi:10.1038/s41586-020-2317-6

82.   Yang Y, Shi Y, Schweighauser M, *et al.* Structures of alpha-synuclein filaments from human brains with Lewy pathology. *Nature*. Oct 2022;610(7933):791-795. doi:10.1038/s41586-022-05319-3

83.   Parnetti L, Chiasserini D, Persichetti E, *et al.* Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. *Mov Disord*. Jul 2014;29(8):1019-27. doi:10.1002/mds.25772

84.   Zheng H, Xie Z, Zhang X, *et al.* Investigation of alpha-Synuclein Species in Plasma Exosomes and the Oligomeric and Phosphorylated alpha-Synuclein as Potential Peripheral Biomarker of Parkinson's Disease. *Neuroscience*. Aug 10 2021;469:79-90. doi:10.1016/j.neuroscience.2021.06.033

85.   Fairfoul G, McGuire LI, Pal S, *et al.* Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. *Ann Clin Transl Neurol*. Oct 2016;3(10):812-818. doi:10.1002/acn3.338

86.   Poggiolini I, Gupta V, Lawton M, *et al.* Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. *Brain*. Apr 18 2022;145(2):584-595. doi:10.1093/brain/awab431

87.   Shahnawaz M, Mukherjee A, Pritzkow S, *et al.* Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy. *Nature*. Feb 2020;578(7794):273-277. doi:10.1038/s41586-020-1984-7

88.   De Luca CMG, Elia AE, Portaleone SM, *et al.* Efficient RT-QuIC seeding activity for alpha-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy. *Transl Neurodegener*. 2019;8:24. doi:10.1186/s40035-019-0164-x

89. Yoo D, Bang JI, Ahn C, *et al.* Diagnostic value of alpha-synuclein seeding amplification assays in alpha-synucleinopathies: A systematic review and meta-analysis. *Parkinsonism Relat Disord.* Nov 2022;104:99-109. doi:10.1016/j.parkreldis.2022.10.007

90. Wang YS, Hu JY, Chen XF, *et al.* Real-time quaking-induced conversion assay is accurate for Lewy body diseases: a meta-analysis. *Neurological Sciences.* Jul 2022;43(7):4125-4132. doi:10.1007/s10072-022-06014-x

91. Peng C, Gathagan RJ, Covell DJ, *et al.* Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. *Nature.* May 2018;557(7706):558-563. doi:10.1038/s41586-018-0104-4

92. Wang Z, Becker K, Donadio V, *et al.* Skin alpha-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. *JAMA Neurol.* Sep 28 2020;doi:10.1001/jamaneurol.2020.3311

93. Manne S, Kondru N, Jin H, *et al.* alpha-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients. *Mov Disord.* Feb 2020;35(2):268-278. doi:10.1002/mds.27907

94. Chahine LM, Beach TG, Adler CH, *et al.* Central and peripheral alpha-synuclein in Parkinson disease detected by seed amplification assay. *Ann Clin Transl Neurol.* May 2023;10(5):696-705. doi:10.1002/acn3.51753

95. Vivacqua G, Mason M, De Bartolo MI, *et al.* Salivary alpha-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson's Disease. *Mov Disord.* Jan 2023;38(1):153-155. doi:10.1002/mds.29246

96. Okuzumi A, Hatano T, Matsumoto G, *et al.* Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies. *Nat Med.* May 29 2023;doi:10.1038/s41591-023-02358-9

97. Kluge A, Bunk J, Schaeffer E, *et al.* Detection of neuron-derived pathological alpha-synuclein in blood. *Brain.* Sep 14 2022;145(9):3058-3071. doi:10.1093/brain/awac115

98. Grossauer A, Hemicker G, Krismer F, *et al.* alpha-Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid-A Systematic Review and Meta-Analysis. *Mov Disord Clin Prac.* Mar 15 2023;doi:10.1002/mdc3.13710

99. Wang H, Atik A, Stewart T, *et al.* Plasma alpha-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study. *Neurobiology of Disease*. Aug 2018;116:53-59. doi:10.1016/j.nbd.2018.04.015

100. Niu M, Li Y, Li G, *et al.* A longitudinal study on alpha-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression. *European Journal of Neurology*. Jun 2020;27(6):967-974. doi:10.1111/ene.14208

101. Majbour NK, Vaikath NN, Eusebi P, *et al.* Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. *Mov Disord*. Oct 2016;31(10):1535-1542. doi:10.1002/mds.26754

102. Lin CH, Liu HC, Yang SY, Yang KC, Wu CC, Chiu MJ. Plasma pS129-alpha-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease. *J Clin Med*. Oct 3 2019;8(10)doi:10.3390/jcm8101601

103. Majbour NK, Abdi IY, Dakna M, *et al.* Cerebrospinal alpha-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort. *Mov Disord*. Sep 2021;36(9):2048-2056. doi:10.1002/mds.28611

104. Imam SZ, Zhou Q, Yamamoto A, *et al.* Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. *J Neurosci*. Jan 5 2011;31(1):157-63. doi:10.1523/JNEUROSCI.1833-10.2011

105. Na CH, Sathe G, Rosenthal LS, *et al.* Development of a novel method for the quantification of tyrosine 39 phosphorylated alpha- and beta-synuclein in human cerebrospinal fluid. *Clin Proteomics*. 2020;17:13. doi:10.1186/s12014-020-09277-8

106. Fernandez E, Garcia-Moreno JM, de Pablos AM, Chacon J. May the Evaluation of Nitrosative Stress Through Selective Increase of 3-Nitrotyrosine Proteins Other Than Nitroalbumin and Dominant Tyrosine-125/136 Nitrosylation of Serum -Synuclein Serve for Diagnosis of Sporadic Parkinson's Disease? *Antioxid Redox Sign*. Sep 20 2013;19(9):912-918. doi:10.1089/ars.2013.5250

107. Beach TG, Adler CH, Sue LI, *et al.* Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. *Acta Neuropathol*. Jun 2010;119(6):689-702. doi:10.1007/s00401-010-0664-3

108. Harapan BN, Frydrychowicz C, Classen J, *et al*. No enhanced (p-) alpha-synuclein deposition in gastrointestinal tissue of Parkinson's disease patients. *Parkinsonism Relat Disord*. Nov 2020;80:82-88. doi:10.1016/j.parkreldis.2020.08.020

109. Bu LL, Huang KX, Zheng DZ, *et al*. Alpha-Synuclein Accumulation and Its Phosphorylation in the Enteric Nervous System of Patients Without Neurodegeneration: An Explorative Study. *Front Aging Neurosci*. 2020;12:575481. doi:10.3389/fnagi.2020.575481

110. Murakami H, Tokuda T, El-Agnaf OMA, *et al*. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naive Parkinson's disease. *BMC Neurol*. Jun 4 2019;19(1):113. doi:10.1186/s12883-019-1346-y

111. Agliardi C, Meloni M, Guerini FR, *et al*. Oligomeric alpha-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson's disease. *Neurobiol Dis*. Jan 2021;148:105185. doi:10.1016/j.nbd.2020.105185

112. Rani K, Mukherjee R, Singh E, *et al*. Neuronal exosomes in saliva of Parkinson's disease patients: A pilot study. *Parkinsonism Relat D*. Oct 2019;67:21-23. doi:10.1016/j.parkreldis.2019.09.008

113. Iranzo A, Fairfoul G, Ayudhaya ACN, *et al*. Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. *Lancet Neurol*. Mar 2021;20(3):203-212. doi:10.1016/S1474-4422(20)30449-X

114. Majbour N, Aasly J, Abdi I, *et al*. Disease-Associated alpha-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage. *Neurology*. Nov 22 2022;99(21):e2417-e2427. doi:10.1212/WNL.0000000000201199

115. Chen GF, Xu TH, Yan Y, *et al*. Amyloid beta: structure, biology and structure-based therapeutic development. *Acta Pharmacol Sin*. Sep 2017;38(9):1205-1235. doi:10.1038/aps.2017.28

116. Bentahir M, Nyabi O, Verhamme J, *et al*. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. *J Neurochem*. Feb 2006;96(3):732-42. doi:10.1111/j.1471-4159.2005.03578.x

117. Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G. Tau protein modifications and interactions: their role in function and dysfunction. *Int J Mol Sci*. Mar 18 2014;15(3):4671-713. doi:10.3390/ijms15034671

118. Irwin DJ, Cohen TJ, Grossman M*, et al*. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. *Brain*. Mar 2012;135(Pt 3):807-18. doi:10.1093/brain/aws013

119. Yoshida M. Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. *Neuropathology*. Dec 2014;34(6):555-70. doi:10.1111/neup.12143

120. Aerts MB, Esselink RA, Bloem BR, Verbeek MM. Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. *Mov Disord*. Jan 2011;26(1):169-73. doi:10.1002/mds.23341

121. Constantinides VC, Paraskevas GP, Emmanouilidou E*, et al*. CSF biomarkers beta-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. *J Neurol Sci*. Nov 15 2017;382:91-95. doi:10.1016/j.jns.2017.09.039

122. Saijo E, Metrick MA, Koga S*, et al*. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration (vol 52, pg 127, 2019). *Acta Neuropathologica*. Jan 2020;139(1):79-81. doi:10.1007/s00401-019-02092-y

123. Dubois B, Feldman HH, Jacova C*, et al*. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *Lancet Neurol*. Jun 2014;13(6):614-29. doi:10.1016/S1474-4422(14)70090-0

124. Kurata T, Kawarabayashi T, Murakami T*, et al*. Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1. *J Neurosci Res*. Aug 1 2007;85(10):2246-52. doi:10.1002/jnr.21352

125. Parnetti L, Tiraboschi P, Lanari A*, et al*. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. *Biol Psychiatry*. Nov 15 2008;64(10):850-5. doi:10.1016/j.biopsych.2008.02.016

126. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and

cognitive decline. *J Neurosci*. May 26 2010;30(21):7281-9. doi:10.1523/JNEUROSCI.0490-10.2010

127.   Lin CH, Yang SY, Horng HE*, et al*. Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes. *Front Aging Neurosci*. 2018;10:123. doi:10.3389/fnagi.2018.00123

128.   Guo JL, Covell DJ, Daniels JP*, et al*. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. *Cell*. Jul 3 2013;154(1):103-17. doi:10.1016/j.cell.2013.05.057

129.   Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. *J Neural Transm (Vienna)*. Mar 2002;109(3):329-39. doi:10.1007/s007020200027

130.   Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. *Nat Rev Neurosci*. Sep 2013;14(9):626-36. doi:10.1038/nrn3549

131.   Siderowf A, Xie SX, Hurtig H*, et al*. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. *Neurology*. Sep 21 2010;75(12):1055-61. doi:10.1212/WNL.0b013e3181f39a78

132.   Alves G, Lange J, Blennow K*, et al*. CSF Abeta42 predicts early-onset dementia in Parkinson disease. *Neurology*. May 20 2014;82(20):1784-90. doi:10.1212/WNL.0000000000000425

133.   Blennow K, Biscetti L, Eusebi P, Parnetti L. Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice. *Mov Disord*. Jun 2016;31(6):836-47. doi:10.1002/mds.26656

134.   Zetterberg H. Plasma amyloid beta-quo vadis? *Neurobiol Aging*. Oct 2015;36(10):2671-3. doi:10.1016/j.neurobiolaging.2015.07.021

135.   Teunissen CE, Chiu MJ, Yang CC*, et al*. Plasma Amyloid-beta (Abeta42) Correlates with Cerebrospinal Fluid Abeta42 in Alzheimer's Disease. *J Alzheimers Dis*. 2018;62(4):1857-1863. doi:10.3233/JAD-170784

136. Chojdak-Lukasiewicz J, Malodobra-Mazur M, Zimny A, Noga L, Paradowski B. Plasma tau protein and Abeta42 level as markers of cognitive impairment in patients with Parkinson's disease. *Adv Clin Exp Med*. Jan 2020;29(1):115-121. doi:10.17219/acem/112058

137. Chen NC, Chen HL, Li SH, *et al*. Plasma Levels of alpha-Synuclein, Abeta-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson's Disease. *Front Aging Neurosci*. 2020;12:112. doi:10.3389/fnagi.2020.00112

138. Randall J, Mortberg E, Provuncher GK, *et al*. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. *Resuscitation*. Mar 2013;84(3):351-6. doi:10.1016/j.resuscitation.2012.07.027

139. Lin WT, Shaw JS, Cheng FY, Chen PH. Plasma total tau predicts executive dysfunction in Parkinson's disease. *Acta Neurol Scand*. Jan 2022;145(1):30-37. doi:10.1111/ane.13517

140. Chung CC, Chan L, Chen JH, Bamodu OA, Chiu HW, Hong CT. Plasma extracellular vesicles tau and beta-amyloid as biomarkers of cognitive dysfunction of Parkinson's disease. *FASEB J*. Oct 2021;35(10):e21895. doi:10.1096/fj.202100787R

141. Chan L, Chung CC, Hsieh YC, Wu RM, Hong CT. Plasma extracellular vesicle tau, beta-amyloid, and alpha-synuclein and the progression of Parkinson's disease: a follow-up study. *Ther Adv Neurol Disord*. 2023;16:17562864221150329. doi:10.1177/17562864221150329

142. Blommer J, Pitcher T, Mustapic M, *et al*. Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease. *Brain*. Jul 14 2022;doi:10.1093/brain/awac258

143. Verde F. Tau proteins in blood as biomarkers of Alzheimer's disease and other proteinopathies. *J Neural Transm*. Feb 2022;129(2):239-259. doi:10.1007/s00702-022-02471-y

144. Batzu L, Rota S, Hye A, *et al*. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease. *NPJ Parkinsons Dis*. Nov 12 2022;8(1):154. doi:10.1038/s41531-022-00384-x

145. Pagonabarraga J, Perez-Gonzalez R, Bejr-Kasem H, *et al*. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease. *Parkinsonism Relat Disord*. Dec 2022;105:132-138. doi:10.1016/j.parkreldis.2022.05.020

146. Chiu MJ, Yang SY, Chen TF, *et al*. Synergistic Association between Plasma A beta(1-42) and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia. *Acs Chem Neurosci*. Apr 21 2021;12(8):1376-1383. doi:10.1021/acschemneuro.1c00010

147. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. *Science*. Aug 19 2016;353(6301):777-83. doi:10.1126/science.aag2590

148. Su W, Chen HB, Li SH, Wu DY. Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients. *Clin Neurol Neurosur*. May 2012;114(4):372-375. doi:10.1016/j.clineuro.2011.11.002

149. Oeckl P, Halbgebauer S, Anderl-Straub S, *et al*. Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. *Journal of Alzheimers Disease*. 2019;67(2):481-488. doi:10.3233/Jad-180325

150. Olsson B, Constantinescu R, Holmberg B, Andreasen N, Blennow K, Zetterberg H. The glial marker YKL-40 is decreased in synucleinopathies. *Mov Disord*. Nov 2013;28(13):1882-5. doi:10.1002/mds.25589

151. Wennstrom M, Surova Y, Hall S, *et al*. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. *PLoS One*. 2015;10(8):e0135458. doi:10.1371/journal.pone.0135458

152. Magdalinou NK, Paterson RW, Schott JM, *et al*. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. *J Neurol Neurosurg Psychiatry*. Nov 2015;86(11):1240-7. doi:10.1136/jnnp-2014-309562

153. Tang Y, Han L, Li S, *et al*. Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia. *NPJ Parkinsons Dis*. Feb 9 2023;9(1):23. doi:10.1038/s41531-023-00447-7

154. Munoz-Delgado L, Macias-Garcia D, Jesus S, *et al*. Peripheral Immune Profile and Neutrophil-to-Lymphocyte Ratio in Parkinson's Disease. *Mov Disord*. Oct 2021;36(10):2426-2430. doi:10.1002/mds.28685

155. Alvarez-Luquin DD, Arce-Sillas A, Leyva-Hernandez J, *et al*. Regulatory impairment in untreated Parkinson's disease is not restricted to Tregs: other regulatory populations are also involved. *J Neuroinflammation*. Nov 11 2019;16(1):212. doi:10.1186/s12974-019-1606-1

156. Kustrimovic N, Comi C, Magistrelli L, *et al*. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naive and drug-treated patients. *J Neuroinflammation*. Jul 12 2018;15(1):205. doi:10.1186/s12974-018-1248-8

157. Rocha NP, Assis F, Scalzo PL, *et al*. Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson's Disease. *Mol Neurobiol*. Feb 2018;55(2):1488-1497. doi:10.1007/s12035-017-0404-y

158. Sun C, Zhao Z, Yu W, *et al*. Abnormal subpopulations of peripheral blood lymphocytes are involved in Parkinson's disease. *Ann Transl Med*. Nov 2019;7(22):637. doi:10.21037/atm.2019.10.105

159. Sanjari Moghaddam H, Ghazi Sherbaf F, Mojtahed Zadeh M, Ashraf-Ganjouei A, Aarabi MH. Association Between Peripheral Inflammation and DATSCAN Data of the Striatal Nuclei in Different Motor Subtypes of Parkinson Disease. *Front Neurol*. 2018;9:234. doi:10.3389/fneur.2018.00234

160. Munoz-Delgado L, Labrador-Espinosa MA, Macias-Garcia D, *et al*. Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease. *Movement Disord*. Mar 13 2023;doi:10.1002/mds.29369

161. Magistrelli L, Storelli E, Rasini E, *et al*. Relationship between circulating CD4+ T lymphocytes and cognitive impairment in patients with Parkinson's disease. *Brain Behav Immun*. Oct 2020;89:668-674. doi:10.1016/j.bbi.2020.07.005

162. Saunders JA, Estes KA, Kosloski LM, *et al*. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. *J Neuroimmune Pharmacol*. Dec 2012;7(4):927-38. doi:10.1007/s11481-012-9402-z

163. Karaaslan Z, Kahraman OT, Sanli E, *et al*. Inflammation and regulatory T cell genes are differentially expressed in peripheral blood mononuclear cells of Parkinson's disease patients. *Sci Rep*. Jan 27 2021;11(1):2316. doi:10.1038/s41598-021-81961-7

164. Akil E, Bulut A, Kaplan I, Ozdemir HH, Arslan D, Aluclu MU. The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson's disease. *Neurol Sci*. Mar 2015;36(3):423-8. doi:10.1007/s10072-014-1976-1

165. Jin H, Gu HY, Mao CJ, Chen J, Liu CF. Association of inflammatory factors and aging in Parkinson's disease. *Neurosci Lett*. Sep 25 2020;736:135259. doi:10.1016/j.neulet.2020.135259

166. Qiu X, Xiao Y, Wu J, Gan L, Huang Y, Wang J. C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis. *Front Neurol*. 2019;10:384. doi:10.3389/fneur.2019.00384

167. Vesely B, Dufek M, Thon V*, et al*. Interleukin 6 and complement serum level study in Parkinson's disease. *J Neural Transm (Vienna)*. May 2018;125(5):875-881. doi:10.1007/s00702-018-1857-5

168. Karpenko MN, Vasilishina AA, Gromova EA, Muruzheva ZM, Miliukhina IV, Bernadotte A. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-alpha levels in CSF and serum in relation to the clinical diversity of Parkinson's disease. *Cell Immunol*. May 2018;327:77-82. doi:10.1016/j.cellimm.2018.02.011

169. Kim R, Kim HJ, Kim A*, et al*. Peripheral blood inflammatory markers in early Parkinson's disease. *J Clin Neurosci*. Dec 2018;58:30-33. doi:10.1016/j.jocn.2018.10.079

170. Dufek M, Hamanova M, Lokaj J*, et al*. Serum inflammatory biomarkers in Parkinson's disease. *Parkinsonism Relat Disord*. May 2009;15(4):318-20. doi:10.1016/j.parkreldis.2008.05.014

171. Kouchaki E, Kakhaki RD, Tamtaji OR*, et al*. Increased serum levels of TNF-alpha and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. *Clin Neurol Neurosurg*. Mar 2018;166:76-79. doi:10.1016/j.clineuro.2018.01.022

172. Wang XM, Zhang YG, Li AL*, et al*. Relationship between levels of inflammatory cytokines in the peripheral blood and the severity of depression and anxiety in patients with Parkinson's disease. *Eur Rev Med Pharmaco*. Sep 2016;20(18):3853-3856.

173. Gupta V, Garg RK, Khattri S. Levels of IL-8 and TNF-alpha decrease in Parkinson's disease. *Neurol Res*. Feb 2016;38(2):98-102. doi:10.1080/01616412.2015.1133026

1 174.   Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor
2 symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in
3 serum. *PLoS One*. 2012;7(10):e47387. doi:10.1371/journal.pone.0047387

4 175.   Schroder JB, Pawlowski M, Meyer Zu Horste G, *et al*. Immune Cell Activation in the
5 Cerebrospinal Fluid of Patients With Parkinson's Disease. *Front Neurol*. 2018;9:1081.
6 doi:10.3389/fneur.2018.01081

7 176.   Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Aberrations in Peripheral Inflammatory
8 Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis. *JAMA Neurol*.
9 Nov 1 2016;73(11):1316-1324. doi:10.1001/jamaneurol.2016.2742

10 177.   Menza M, Dobkin RD, Marin H, *et al*. The role of inflammatory cytokines in cognition
11 and other non-motor symptoms of Parkinson's disease. *Psychosomatics*. Nov-Dec
12 2010;51(6):474-9. doi:10.1176/appi.psy.51.6.474

13 178.   Sawada H, Oeda T, Umemura A, *et al*. Baseline C-Reactive Protein Levels and Life
14 Prognosis in Parkinson Disease. *PLoS One*. 2015;10(7):e0134118.
15 doi:10.1371/journal.pone.0134118

16 179.   Rentzos M, Nikolaou C, Andreadou E, *et al*. Circulating interleukin-15 and RANTES
17 chemokine in Parkinson's disease. *Acta Neurol Scand*. Dec 2007;116(6):374-9.
18 doi:10.1111/j.1600-0404.2007.00894.x

19 180.   Tang P, Chong L, Li X, *et al*. Correlation between serum RANTES levels and the
20 severity of Parkinson's disease. *Oxid Med Cell Longev*. 2014;2014:208408.
21 doi:10.1155/2014/208408

22 181.   Williams-Gray CH, Wijeyekoon R, Yarnall AJ, *et al*. Serum immune markers and disease
23 progression in an incident Parkinson's disease cohort (ICICLE-PD). *Mov Disord*. Jul
24 2016;31(7):995-1003. doi:10.1002/mds.26563

25 182.   Rathnayake D, Chang T, Udagama P. Selected serum cytokines and nitric oxide as
26 potential multi-marker biosignature panels for Parkinson disease of varying durations: a case-
27 control study. *BMC Neurol*. Apr 6 2019;19(1):56. doi:10.1186/s12883-019-1286-6

183. Kalia LV, Lang AE, Hazrati LN, *et al*. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. *JAMA Neurol*. Jan 2015;72(1):100-5. doi:10.1001/jamaneurol.2014.2704

184. Sosero YL, Gan-Or Z. LRRK2 and Parkinson's disease: from genetics to targeted therapy. *Ann Clin Transl Neurol*. Apr 6 2023;doi:10.1002/acn3.51776

185. Brockmann K, Quadalti C, Lerche S, *et al*. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies. *Acta Neuropathol Commun*. Oct 30 2021;9(1):175. doi:10.1186/s40478-021-01276-6

186. Fraser KB, Rawlins AB, Clark RG, *et al*. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. *Movement Disord*. Oct 2016;31(10):1543-1550. doi:10.1002/mds.26686

187. Wang SJ, Liu ZY, Ye T, *et al*. Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. *Acta Neuropathol Com*. Nov 22 2017;5doi:ARTN 86

10.1186/s40478-017-0492-y

188. Jennings D, Huntwork-Rodriguez S, Vissers M, *et al*. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease. *Mov Disord*. Mar 2023;38(3):386-398. doi:10.1002/mds.29297

189. Papadimitriou D, Antonelou R, Miligkos M, *et al*. Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study. *Movement Disord*. Aug 2016;31(8):1226-1230. doi:10.1002/mds.26615

190. Brockmann K, Srulijes K, Pflederer S, *et al*. GBA-Associated Parkinson's Disease: Reduced Survival and More Rapid Progression in a Prospective Longitudinal Study. *Movement Disord*. Mar 2015;30(3):407-411. doi:10.1002/mds.26071

191. Brockmann K, Schulte C, Deuschle C, *et al*. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. *Parkinsonism Relat D*. Dec 2015;21(12):1427-1434. doi:10.1016/j.parkreldis.2015.10.008

192. Pankratz N, Byder L, Halter C, *et al*. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. *Mov Disord*. Jan 2006;21(1):45-9. doi:10.1002/mds.20663

193. Liu JY, Ma LZ, Wang J, *et al*. Age-Related Association Between APOE varepsilon4 and Cognitive Progression in de novo Parkinson's Disease. *J Alzheimers Dis*. 2023;91(3):1121-1132. doi:10.3233/JAD-220976

194. Tan MMX, Lawton MA, Jabbari E, *et al*. Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. *Mov Disord*. Feb 2021;36(2):424-433. doi:10.1002/mds.28342

195. Winder-Rhodes SE, Evans JR, Ban M, *et al*. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. *Brain*. Feb 2013;136:392-399. doi:10.1093/brain/aws318

196. Davis MY, Johnson CO, Leverenz JB, *et al*. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. *Jama Neurology*. Oct 1 2016;73(10):1217-1224. doi:10.1001/jamaneurol.2016.2245

197. Liu GQ, Boot B, Locascio JJ, *et al*. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. *Annals of Neurology*. Nov 2016;80(5):674-685. doi:10.1002/ana.24781

198. Iwaki H, Blauwendraat C, Leonard HL. Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts (vol 5, e348, 2019). *Neurol-Genet*. Aug 2019;5(4)doi:ARTN e354

10.1212/NXG.0000000000000354

199. Lawton M, Tan MM, Ben-Shlomo Y, *et al*. Genetics of validated Parkinson's disease subtypes in the Oxford Discovery and Tracking Parkinson's cohorts. *J Neurol Neurosurg Psychiatry*. Jun 22 2022;93(9):952-9. doi:10.1136/jnnp-2021-327376

200. Liu G, Peng J, Liao Z, *et al*. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. *Nat Genet*. Jun 2021;53(6):787-793. doi:10.1038/s41588-021-00847-6

201. Kern F, Krammes L, Danz K, *et al*. Validation of human microRNA target pathways enables evaluation of target prediction tools. *Nucleic Acids Res*. Jan 11 2021;49(1):127-144. doi:10.1093/nar/gkaa1161

202. Ding H, Huang Z, Chen M, *et al*. Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease. *Parkinsonism Relat Disord*. Jan 2016;22:68-73. doi:10.1016/j.parkreldis.2015.11.014

203. Caldi Gomes L, Roser AE, Jain G, *et al*. MicroRNAs from extracellular vesicles as a signature for Parkinson's disease. *Clin Transl Med*. Apr 2021;11(4):e357. doi:10.1002/ctm2.357

204. Tomlinson PR, Zheng Y, Fischer R, *et al*. Identification of distinct circulating exosomes in Parkinson's disease. *Ann Clin Transl Neur*. Apr 2015;2(4):353-361. doi:10.1002/acn3.175

205. Gui YX, Liu H, Zhang LS, Lv W, Hu XY. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. *Oncotarget*. Nov 10 2015;6(35):37043-37053. doi:DOI 10.18632/oncotarget.6158

206. O'Regan G, deSouza RM, Balestrino R, Schapira AH. Glucocerebrosidase Mutations in Parkinson Disease. *J Parkinsons Dis*. 2017;7(3):411-422. doi:10.3233/JPD-171092

207. Sevlever D, Jiang PZ, Yen SHC. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. *Biochemistry*. Sep 9 2008;47(36):9678-9687. doi:10.1021/bi800699v

208. Lerche S, Schulte C, Wurster I, *et al*. The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PD(GBA). *Mov Disord*. May 2021;36(5):1216-1228. doi:10.1002/mds.28472

209. Parnetti L, Paciotti S, Eusebi P, *et al*. Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson's disease patients. *Mov Disord*. Oct 2017;32(10):1423-1431. doi:10.1002/mds.27136

210. Omer N, Giladi N, Gurevich T, *et al*. Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity. *Mov Disord*. Mar 2022;37(3):651-652. doi:10.1002/mds.28929

211. Oftedal L, Maple-Grodem J, Dalen I, *et al.* Association of CSF Glucocerebrosidase Activity With the Risk of Incident Dementia in Patients With Parkinson Disease. *Neurology.* Jan 24 2023;100(4):e388-e395. doi:10.1212/WNL.0000000000201418

212. Atashrazm F, Hammond D, Perera G, *et al.* Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease. *Sci Rep-Uk.* Oct 18 2018;8doi:ARTN 15446

10.1038/s41598-018-33921-x

213. Alcalay RN, Levy OA, Waters CC, *et al.* Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. *Brain.* Sep 1 2015;138:2648-2658. doi:10.1093/brain/awv179

214. Mielke MM, Maetzler W, Haughey NJ, *et al.* Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study. *Plos One.* Sep 18 2013;8(9)doi:ARTN e73094

10.1371/journal.pone.0073094

215. den Heijer JM, Cullen VC, Pereira DR, *et al.* A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls. *Mov Disord.* Mar 14 2023;doi:10.1002/mds.29360

216. Nicklas WJ, Saporito M, Basma A, Geller HM, Heikkila RE. Mitochondrial mechanisms of neurotoxicity. *Ann N Y Acad Sci.* May 11 1992;648:28-36. doi:10.1111/j.1749-6632.1992.tb24521.x

217. Larsen SB, Hanss Z, Kruger R. The genetic architecture of mitochondrial dysfunction in Parkinson's disease. *Cell Tissue Res.* Jul 2018;373(1):21-37. doi:10.1007/s00441-017-2768-8

218. Kahle PJ, Waak J, Gasser T. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. *Free Radic Biol Med.* Nov 15 2009;47(10):1354-61. doi:10.1016/j.freeradbiomed.2009.08.003

219. Waragai M, Wei J, Fujita M, *et al.* Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. *Biochem Biophys Res Commun.* Jul 7 2006;345(3):967-72. doi:10.1016/j.bbrc.2006.05.011

220. Waragai M, Nakai M, Wei J, *et al*. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. *Neurosci Lett*. Sep 20 2007;425(1):18-22. doi:10.1016/j.neulet.2007.08.010

221. Salvesen L, Bech S, Lokkegaard A, *et al*. The DJ-1 concentration in cerebrospinal fluid does not differentiate among Parkinsonian syndromes. *Parkinsonism Relat Disord*. Aug 2012;18(7):899-901. doi:10.1016/j.parkreldis.2012.03.013

222. Herbert MK, Eeftens JM, Aerts MB, *et al*. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. *Parkinsonism Relat Disord*. Jan 2014;20(1):112-5. doi:10.1016/j.parkreldis.2013.09.003

223. An C, Pu X, Xiao W, Zhang H. Expression of the DJ-1 protein in the serum of Chinese patients with Parkinson's disease. *Neurosci Lett*. Feb 5 2018;665:236-239. doi:10.1016/j.neulet.2017.12.023

224. Maita C, Tsuji S, Yabe I, *et al*. Secretion of DJ-1 into the serum of patients with Parkinson's disease. *Neuroscience Letters*. Jan 24 2008;431(1):86-89. doi:10.1016/j.neulet.2007.11.027

225. Shi M, Zabetian CP, Hancock AM, *et al*. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. *Neurosci Lett*. Aug 9 2010;480(1):78-82. doi:10.1016/j.neulet.2010.06.009

226. Swatek KN, Usher JL, Kueck AF, *et al*. Insights into ubiquitin chain architecture using Ub-clipping. *Nature*. Aug 22 2019;572(7770):533-+. doi:10.1038/s41586-019-1482-y

227. Hou X, Fiesel FC, Truban D, *et al*. Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. *Autophagy*. 2018;14(8):1404-1418. doi:10.1080/15548627.2018.1461294

228. Fiesel FC, Ando M, Hudec R, *et al*. (Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation. *Embo Rep*. Sep 2015;16(9):1114-1130. doi:DOI 10.15252/embr.201540514

229. Piccinin E, Sardanelli AM, Seibel P, Moschetta A, Cocco T, Villani G. PGC-1s in the Spotlight with Parkinson's Disease. *Int J Mol Sci*. Mar 28 2021;22(7)doi:10.3390/ijms22073487

230. Eschbach J, von Einem B, Muller K, *et al*. Mutual exacerbation of peroxisome proliferator-activated receptor gamma coactivator 1alpha deregulation and alpha-synuclein oligomerization. *Ann Neurol*. Jan 2015;77(1):15-32. doi:10.1002/ana.24294

231. Yang XD, Qian YW, Xu SQ*, et al*. Expression of the gene coading for PGC-1alpha in peripheral blood leukocytes and related gene variants in patients with Parkinson's disease. *Parkinsonism Relat Disord*. Jun 2018;51:30-35. doi:10.1016/j.parkreldis.2018.02.037

232. Yang X, Xu S, Qian Y, He X, Chen S, Xiao Q. Hypermethylation of the Gene Coding for PGC-1alpha in Peripheral Blood Leukocytes of Patients With Parkinson's Disease. *Front Neurosci*. 2020;14:97. doi:10.3389/fnins.2020.00097

233. Dossi G, Squarcina L, Rango M. In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson's Disease. *Metabolites*. Dec 28 2019;10(1)doi:10.3390/metabo10010019

234. Davis RL, Wong SL, Carling PJ, Payne T, Sue CM, Bandmann O. Serum FGF-21, GDF-15, and blood mtDNA copy number are not biomarkers of Parkinson disease. *Neurol-Clin Pract*. Feb 2020;10(1):40-46. doi:10.1212/Cpj.0000000000000702

235. Chohan H, Senkevich K, Patel RK, *et al*. Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. *Movement Disord*. Jun 2021;36(6):1420-1429. doi:10.1002/mds.28551

236. Kotagal V, Albin RL, Muller MLTM, Koeppe RA, Frey KA, Bohnen NI. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. *Parkinsonism Relat D*. May 2013;19(5):522-526. doi:10.1016/j.parkreldis.2013.01.016

237. Bosco D, Plastino M, Cristiano D*, et al*. Dementia is associated with Insulin Resistance in patients with Parkinson's Disease. *Journal of the Neurological Sciences*. Apr 15 2012;315(1-2):39-43. doi:10.1016/j.jns.2011.12.008

238. Athauda D, Evans J, Wernick A*, et al*. The Impact of Type 2 Diabetes in Parkinson's Disease. *Movement Disord*. Jun 14 2022;doi:10.1002/mds.29122

239. de Pablo-Fernandez E, Courtney R, Rockliffe A, Gentleman S, Holton JL, Warner TT. Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased alpha-synuclein, tau, amyloid-beta or vascular pathology. *Neuropath Appl Neuro*. Dec 2021;47(7):1080-1091. doi:10.1111/nan.12728

240. Gao S, Duan C, Gao G, Wang X, Yang H. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. *Int J Biochem Cell Biol*. Jul 2015;64:25-33. doi:10.1016/j.biocel.2015.03.006

241. Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: A new target for disease modification? *Prog Neurobiol*. Oct - Nov 2016;145-146:98-120. doi:10.1016/j.pneurobio.2016.10.001

242. Tremblay F, Brule S, Hee Um S*, et al*. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. *Proc Natl Acad Sci U S A*. Aug 28 2007;104(35):14056-61. doi:10.1073/pnas.0706517104

243. Bassil F, Delamarre A, Canron MH*, et al*. Impaired brain insulin signalling in Parkinson's disease. *Neuropathol Appl Neurobiol*. Feb 2022;48(1):e12760. doi:10.1111/nan.12760

244. Bassil F, Canron MH, Vital A*, et al*. Insulin resistance and exendin-4 treatment for multiple system atrophy. *Brain*. May 1 2017;140(5):1420-1436. doi:10.1093/brain/awx044

245. Athauda D, Gulyani S, Karnati HK*, et al*. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. *JAMA Neurol*. Apr 1 2019;76(4):420-429. doi:10.1001/jamaneurol.2018.4304

246. Kapogiannis D, Mustapic M, Shardell MD*, et al*. Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging. *JAMA Neurol*. Nov 1 2019;76(11):1340-1351. doi:10.1001/jamaneurol.2019.2462

247. Hogg E, Athreya K, Basile C, Tan EE, Kaminski J, Tagliati M. High Prevalence of Undiagnosed Insulin Resistance in Non-Diabetic Subjects with Parkinson's Disease. *J Parkinsons Dis*. 2018;8(2):259-265. doi:10.3233/JPD-181305

248. Horvath I, Wittung-Stafshede P. Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson's disease. *P Natl Acad Sci USA*. Nov 1 2016;113(44):12473-12477. doi:10.1073/pnas.1610371113

249. Martinez-Valbuena I, Amat-Villegas I, Valenti-Azcarate R*, et al*. Interaction of amyloidogenic proteins in pancreatic beta cells from subjects with synucleinopathies. *Acta Neuropathologica*. Jun 2018;135(6):877-886. doi:10.1007/s00401-018-1832-0

250.   Markaki I, Ntetsika T, Sorjonen K, Svenningsson P, BioPark Study G. Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease. *Mov Disord*. Jun 2021;36(6):1430-1434. doi:10.1002/mds.28545

251.   Huxford B, Haque T, Joseph AB, *et al*. Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity. *Mov Disord*. Feb 2022;37(2):427-428. doi:10.1002/mds.28829

252.   Uyar M, Lezius S, Buhmann C, *et al*. Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study). *Mov Disord*. Jun 2022;37(6):1299-1304. doi:10.1002/mds.29009

253.   Vijiaratnam N, Lawton M, Real R, *et al*. Diabetes and Neuroaxonal Damage in Parkinson's Disease. *Mov Disord*. Jul 2022;37(7):1568-1569. doi:10.1002/mds.29067

254.   Girges C, Vijiaratnam N, Athauda D, Auld G, Gandhi S, Foltynie T. The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. *Drugs Aging*. May 2021;38(5):355-373. doi:10.1007/s40266-021-00853-7

255.   Gonzalez AC, Belbin O. Fluid markers of synapse degeneration in synucleinopathies. *J Neural Transm*. Feb 2022;129(2):187-206. doi:10.1007/s00702-022-02467-8

256.   Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. beta-synuclein inhibits alpha-synuclein aggregation: A possible role as an anti-parkinsonian factor. *Neuron*. Oct 25 2001;32(2):213-223. doi:Doi 10.1016/S0896-6273(01)00462-7

257.   Oeckl P, Metzger F, Nagl M, *et al*. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. *Mol Cell Proteomics*. Oct 2016;15(10):3126-3138. doi:10.1074/mcp.M116.059915

258.   Halbgebauer S, Oeckl P, Steinacker P, *et al*. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. *J Neurol Neurosur Ps*. Apr 2021;92(4):349-356. doi:10.1136/jnnp-2020-324306

259. Sjogren M, Minthon L, Davidsson P, *et al.* CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. *J Neural Transm*. 2000;107(5):563-579. doi:DOI 10.1007/s007020070079

260. Remnestal J, Just D, Mitsios N, *et al.* CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. *Proteom Clin Appl*. Dec 2016;10(12):1242-1253. doi:10.1002/prca.201500150

261. Sandelius A, Portelius E, Kallen A, *et al.* Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. *Alzheimers Dement*. Jan 2019;15(1):55-64. doi:10.1016/j.jalz.2018.08.006

262. Chatterjee M, van Steenoven I, Huisman E, *et al.* Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. *Biomolecules*. Aug 2020;10(8)doi:ARTN 1177

10.3390/biom10081177

263. Enache D, Pereira JB, Jelic V, *et al.* Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. *Journal of Alzheimers Disease*. 2020;77(3):1143-1155. doi:10.3233/Jad-200498

264. Bereczki E, Bogstedt A, Hoglund K, *et al.* Synaptic proteins in CSF relate to Parkinson's disease stage markers. *Npj Parkinson Dis*. Feb 8 2017;3doi:ARTN 7

10.1038/s41531-017-0008-2

265. Selnes P, Stav AL, Johansen KK, *et al.* Impaired synaptic function is linked to cognition in Parkinson's disease. *Ann Clin Transl Neur*. Oct 2017;4(10):700-713. doi:10.1002/acn3.446

266. Hall S, Janelidze S, Zetterberg H, *et al.* Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders. *Movement Disord*. Mar 2020;35(3):513-518. doi:10.1002/mds.27950

267. Portelius E, Olsson B, Hoglund K, *et al.* Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. *Acta Neuropathologica*. Sep 2018;136(3):363-376. doi:10.1007/s00401-018-1851-x

268.   Wellington H, Paterson RW, Portelius E, *et al*. Increased CSF neurogranin concentration is specific to Alzheimer disease. *Neurology*. Mar 1 2016;86(9):829-835. doi:10.1212/Wnl.0000000000002423

269.   Janelidze S, Hertze J, Zetterberg H, *et al*. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. *Ann Clin Transl Neur*. Jan 2016;3(1):12-20. doi:10.1002/acn3.266

270.   van Steenoven I, Noli B, Cocco C, *et al*. VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. *International Journal of Molecular Sciences*. Oct 2019;20(19)doi:ARTN 4674

10.3390/ijms20194674

271.   van Steenoven I, Koel-Simmelink MJA, Vergouw LJM, *et al*. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. *Molecular Neurodegeneration*. Jun 18 2020;15(1)doi:ARTN 36

10.1186/s13024-020-00388-2

272.   Nilsson J, Constantinescu J, Nellgard B, *et al*. Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction Are Altered in Parkinson's Disease and Related Disorders. *Movement Disord*. Dec 12 2022;doi:10.1002/mds.29287

273.   Lerche S, Sjodin S, Brinkmalm A, *et al*. CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB. *Movement Disord*. Nov 2021;36(11):2595-2604. doi:10.1002/mds.28704

274.   Agliardi C, Meloni M, Guerini FR, *et al*. Oligomeric alpha-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson's disease. *Neurobiology of Disease*. Jan 2021;148doi:ARTN 105185

10.1016/j.nbd.2020.105185

275.   Boiten WA, van Steenoven I, Xiao MF, *et al*. Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF (vol 10, 38, 2021). *Cells*. Feb 2022;11(4)doi:ARTN 652

10.3390/cells11040652

276. Lewitt PA, Galloway MP, Matson W, *et al*. Markers of Dopamine Metabolism in Parkinsons-Disease. *Neurology*. Nov 1992;42(11):2111-2117. doi:Doi 10.1212/Wnl.42.11.2111

277. LeWitt P, Schultz L, Auinger P, Lu M, DATATOP PSG. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. *Brain Res*. Aug 23 2011;1408:88-97. doi:10.1016/j.brainres.2011.06.057

278. Chia LG, Cheng FC, Kuo JS. Monoamines and Their Metabolites in Plasma and Lumbar Cerebrospinal-Fluid of Chinese Patients with Parkinsons-Disease. *Journal of the Neurological Sciences*. Jun 1993;116(2):125-134. doi:Doi 10.1016/0022-510x(93)90316-Q

279. Herbert MK, Kuiperij HB, Bloem BR, Verbeek MM. Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls. *Journal of Neurology*. Dec 2013;260(12):3129-3133. doi:10.1007/s00415-013-7126-5

280. Czech C, Berndt P, Busch K, *et al*. Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid. *Plos One*. Feb 16 2012;7(2)doi:ARTN e31501

10.1371/journal.pone.0031501

281. Eldrup E, Mogensen P, Jacobsen J, Pakkenberg H, Christensen NJ. Csf and Plasma-Concentrations of Free Norepinephrine, Dopamine, 3,4-Dihydroxyphenylacetic Acid (Dopac), 3,4-Dihydroxyphenylalanine (Dopa), and Epinephrine in Parkinsons-Disease. *Acta Neurologica Scandinavica*. Aug 1995;92(2):116-121.

282. Stefani A, Pierantozzi M, Olivola E, *et al*. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. *Neurochem Int*. May 2017;105:58-63. doi:10.1016/j.neuint.2017.01.007

283. Kremer T, Taylor KI, Siebourg-Polster J, *et al*. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. *Movement Disord*. Aug 2021;36(8):1972-1978. doi:10.1002/mds.28608

284. Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments and Neurofilament Proteins in Health and Disease. *Cold Spring Harb Perspect Biol*. Apr 3 2017;9(4)doi:10.1101/cshperspect.a018309

285.   Bridel C, van Wieringen WN, Zetterberg H, *et al*. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. *JAMA Neurol*. Jun 17 2019;doi:10.1001/jamaneurol.2019.1534

286.   Diekamper E, Brix B, Stocker W, *et al*. Neurofilament Levels Are Reflecting the Loss of Presynaptic Dopamine Receptors in Movement Disorders. *Front Neurosci*. 2021;15:690013. doi:10.3389/fnins.2021.690013

287.   Ye R, Locascio JJ, Goodheart AE, Quan M, Zhang B, Gomperts SN. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study. *Parkinsonism Relat Disord*. Apr 2021;85:11-16. doi:10.1016/j.parkreldis.2021.02.008

288.   Gaetani L, Hoglund K, Parnetti L, *et al*. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. *Alzheimers Res Ther*. Jan 23 2018;10(1):8. doi:10.1186/s13195-018-0339-1

289.   Bridel C, van Wieringen WN, Zetterberg H, *et al*. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. *JAMA Neurol*. Sep 1 2019;76(9):1035-1048. doi:10.1001/jamaneurol.2019.1534

290.   Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. *Mov Disord*. Jan 1998;13(1):70-7. doi:10.1002/mds.870130116

291.   Hall S, Ohrfelt A, Constantinescu R, *et al*. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. *Arch Neurol*. Nov 2012;69(11):1445-52. doi:10.1001/archneurol.2012.1654

292.   Hansson O, Janelidze S, Hall S, *et al*. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. *Neurology*. Mar 7 2017;88(10):930-937. doi:10.1212/WNL.0000000000003680

293.   Wang SY, Chen W, Xu W, *et al*. Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis. *J Alzheimers Dis*. 2019;72(4):1353-1361. doi:10.3233/JAD-190615

294.   Marques TM, van Rumund A, Oeckl P, *et al*. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. *Neurology*. Mar 26 2019;92(13):e1479-e1486. doi:10.1212/WNL.0000000000007179

295.   Lin YS, Lee WJ, Wang SJ, Fuh JL. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. *Sci Rep*. Nov 26 2018;8(1):17368. doi:10.1038/s41598-018-35766-w

296.   Lin CH, Li CH, Yang KC, *et al*. Blood NfL: A biomarker for disease severity and progression in Parkinson disease. *Neurology*. Sep 10 2019;93(11):e1104-e1111. doi:10.1212/WNL.0000000000008088

297.   Mollenhauer B, Dakna M, Kruse N, *et al*. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. *Mov Disord*. Nov 2020;35(11):1999-2008. doi:10.1002/mds.28206

298.   Chung CC, Chan L, Chen JH, Bamodu OA, Hong CT. Neurofilament light chain level in plasma extracellular vesicles and Parkinson's disease. *Ther Adv Neurol Disord*. 2020;13:1756286420975917. doi:10.1177/1756286420975917

299.   Vijiaratnam N, Lawton M, Heslegrave AJ, *et al*. Combining biomarkers for prognostic modelling of Parkinson's disease. *J Neurol Neurosurg Psychiatry*. May 16 2022;doi:10.1136/jnnp-2021-328365

300.   Potter-Nerger M, Dutke J, Lezius S, *et al*. Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study. *J Neural Transm (Vienna)*. Mar 2022;129(3):295-300. doi:10.1007/s00702-022-02464-x

301.   Ng ASL, Tan YJ, Yong ACW, *et al*. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease. *Mol Neurodegener*. Jun 5 2020;15(1):33. doi:10.1186/s13024-020-00385-5

302.   Aamodt WW, Waligorska T, Shen J, *et al*. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. *Mov Disord*. Dec 2021;36(12):2945-2950. doi:10.1002/mds.28779

303. Ma LZ, Zhang C, Wang H, *et al*. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease. *J Parkinsons Dis*. 2021;11(3):1117-1127. doi:10.3233/JPD-212535

304. Choe CU, Niemann L, Englisch C, *et al*. Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease. *Mov Disord*. Oct 2020;35(10):1863-1868. doi:10.1002/mds.28129

305. Niemann L, Lezius S, Maceski A, *et al*. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD). *Parkinsonism Relat Disord*. Sep 2021;90:44-48. doi:10.1016/j.parkreldis.2021.07.028

306. Kim R, Jeon B. Serum neurofilament light chain predicts future freezing of gait in Parkinson's disease. *Parkinsonism Relat Disord*. Oct 2021;91:102-104. doi:10.1016/j.parkreldis.2021.08.015

307. Ygland Rodstrom E, Mattsson-Carlgren N, Janelidze S, Hansson O, Puschmann A. Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes. *J Parkinsons Dis*. 2022;12(2):571-584. doi:10.3233/JPD-212866

308. Backstrom DC, Eriksson Domellof M, Linder J, *et al*. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. *JAMA Neurol*. Oct 2015;72(10):1175-82. doi:10.1001/jamaneurol.2015.1449

309. Martinez-Valbuena I, Visanji NP, Olszewska DA, *et al*. Combining Skin alpha-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease. *Movement Disord*. Mar 2022;37(3):648-650. doi:10.1002/mds.28912

310. Compta Y, Painous C, Soto M, *et al*. Combined CSF alpha-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again. *Parkinsonism Relat Disord*. Jun 2022;99:33-41. doi:10.1016/j.parkreldis.2022.05.006

311. Vijiaratnam N, Lawton M, Heslegrave AJ, *et al*. Combining biomarkers for prognostic modelling of Parkinson's disease. *J Neurol Neurosurg Psychiatry*. May 16 2022;93(7):707-15. doi:10.1136/jnnp-2021-328365

312. Gaenslen A, Unmuth B, Godau J, *et al*. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. *Lancet Neurol*. May 2008;7(5):417-24. doi:10.1016/S1474-4422(08)70067-X

313. Li DH, He YC, Liu J, Chen SD. Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson's disease: A Systematic Review and Meta-analysis. *Sci Rep*. Feb 16 2016;6:20863. doi:10.1038/srep20863

314. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. *J Neurol*. Aug 2001;248(8):684-9. doi:10.1007/s004150170114

315. Berg D, Becker G, Zeiler B, *et al*. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. *Neurology*. Sep 22 1999;53(5):1026-31. doi:10.1212/wnl.53.5.1026

316. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. *Mov Disord*. Mar 2005;20(3):383-5. doi:10.1002/mds.20311

317. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. *Neurology*. Jan 1995;45(1):182-4. doi:10.1212/wnl.45.1.182

318. Spiegel J, Hellwig D, Mollers MO, *et al*. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. *Brain*. May 2006;129(Pt 5):1188-93. doi:10.1093/brain/awl042

319. Mitchell T, Lehericy S, Chiu SY, Strafella AP, Stoessl AJ, Vaillancourt DE. Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review. *JAMA Neurol*. Oct 1 2021;78(10):1262-1272. doi:10.1001/jamaneurol.2021.1312

320. Quattrone A, Bianco MG, Antonini A, *et al*. Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-

Parkinsonism From Parkinson's Disease. *Mov Disord*. Jun 2022;37(6):1272-1281. doi:10.1002/mds.28992

321.   Zeighami Y, Fereshtehnejad SM, Dadar M, Collins DL, Postuma RB, Dagher A. Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease. *Neuroimage Clin*. 2019;24:101986. doi:10.1016/j.nicl.2019.101986

322.   Tessa C, Lucetti C, Giannelli M, *et al*. Progression of brain atrophy in the early stages of Parkinson's disease: a longitudinal tensor-based morphometry study in de novo patients without cognitive impairment. *Hum Brain Mapp*. Aug 2014;35(8):3932-44. doi:10.1002/hbm.22449

323.   Mak E, Su L, Williams GB, *et al*. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. *Brain*. Oct 2015;138(Pt 10):2974-86. doi:10.1093/brain/awv211

324.   Mak E, Su L, Williams GB, *et al*. Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. *Neurobiol Aging*. Jul 2017;55:78-90. doi:10.1016/j.neurobiolaging.2017.03.012

325.   Agosta F, Canu E, Stojkovic T, *et al*. The Topography of Brain Damage at Different Stages of Parkinson's Disease. *Human Brain Mapping*. Nov 2013;34(11):2798-2807. doi:10.1002/hbm.22101

326.   Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. *Brain*. Apr 2004;127:791-800. doi:10.1093/brain/awh088

327.   Hanganu A, Bedetti C, Degroot C, *et al*. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. *Brain*. Apr 2014;137:1120-1129. doi:10.1093/brain/awu036

328.   Sterling NW, Wang M, Zhang LJ, *et al*. Stage-dependent loss of cortical gyrification as Parkinson disease "unfolds". *Neurology*. Mar 22 2016;86(12):1143-1151. doi:10.1212/Wnl.0000000000002492

329.   Lehericy S, Vaillancourt DE, Seppi K, *et al*. The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. *Mov Disord*. Apr 2017;32(4):510-525. doi:10.1002/mds.26968

330. Wolters AF, Heijmans M, Michielse S, *et al*. The TRACK-PD study: protocol of a longitudinal ultra-high field imaging study in Parkinson's disease. *BMC Neurol*. Aug 5 2020;20(1):292. doi:10.1186/s12883-020-01874-2

331. Sjostrom H, Granberg T, Westman E, Svenningsson P. Quantitative susceptibility mapping differentiates between parkinsonian disorders. *Parkinsonism Relat D*. Nov 2017;44:51-57. doi:10.1016/j.parkreldis.2017.08.029

332. Biondetti E, Gaurav R, Yahia-Cherif L, *et al*. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease. *Brain*. Sep 1 2020;143(9):2757-2770. doi:10.1093/brain/awaa216

333. Matsuura K, Maeda M, Tabei KI, *et al*. A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson's disease. *Neurosci Lett*. Oct 28 2016;633:112-117. doi:10.1016/j.neulet.2016.09.011

334. Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O, *et al*. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. *Mov Disord*. Jun 2015;30(7):945-52. doi:10.1002/mds.26201

335. Gaurav R, Yahia-Cherif L, Pyatigorskaya N, *et al*. Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker. *Mov Disord*. Jul 2021;36(7):1592-1602. doi:10.1002/mds.28531

336. Ohtsuka C, Sasaki M, Konno K, *et al*. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. *Parkinsonism Relat Disord*. Jul 2014;20(7):755-60. doi:10.1016/j.parkreldis.2014.04.005

337. Nobileau A, Gaurav R, Chougar L, *et al*. Neuromelanin-Sensitive Magnetic Resonance Imaging Changes in the Locus Coeruleus/Subcoeruleus Complex in Patients with Typical and Atypical Parkinsonism. *Mov Disord*. Mar 2023;38(3):479-484. doi:10.1002/mds.29309

338. Meijer FJA, van Rumund A, Fasen BACM, *et al*. Susceptibility-Weighted Imaging Improves the Diagnostic Accuracy of 3T Brain MRI in the Work-Up of Parkinsonism. *Am J Neuroradiol*. Mar 2015;36(3):454-460. doi:10.3174/ajnr.A4140

339. Rossi ME, Ruottinen H, Saunamaki T, Elovaara I, Dastidar P. Imaging Brain Iron and Diffusion Patterns: A Follow-up Study of Parkinson's Disease in the Initial Stages. *Acad Radiol*. Jan 2014;21(1):64-71. doi:10.1016/j.acra.2013.09.018

340. Wieler M, Gee M, Martin WRW. Longitudinal midbrain changes in early Parkinson's disease: Iron content estimated from R-2*/MRI. *Parkinsonism Relat D*. Mar 2015;21(3):179-183. doi:10.1016/j.parkreldis.2014.11.017

341. Cheng Z, He N, Huang P, *et al*. Imaging the Nigrosome 1 in the substantia nigra using susceptibility weighted imaging and quantitative susceptibility mapping: An application to Parkinson's disease. *Neuroimage Clin*. 2020;25:102103. doi:10.1016/j.nicl.2019.102103

342. Mahlknecht P, Krismer F, Poewe W, Seppi K. Meta-Analysis of Dorsolateral Nigral Hyperintensity on Magnetic Resonance Imaging as a Marker for Parkinson's Disease. *Movement Disord*. Apr 2017;32(4):619-623. doi:10.1002/mds.26932

343. Du G, Lewis MM, Sica C, *et al*. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients. *Mov Disord*. Sep 2018;33(9):1423-1431. doi:10.1002/mds.27318

344. Hopes L, Grolez G, Moreau C, *et al*. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages? *Plos One*. Apr 1 2016;11(4)doi:ARTN e0147947

10.1371/journal.pone.0147947

345. Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. *PLoS One*. 2013;8(3):e57904. doi:10.1371/journal.pone.0057904

346. Rolheiser TM, Fulton HG, Good KP, *et al*. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. *J Neurol*. Jul 2011;258(7):1254-60. doi:10.1007/s00415-011-5915-2

347. Vaillancourt DE, Spraker MB, Prodoehl J, *et al*. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. *Neurology*. Apr 21 2009;72(16):1378-84. doi:10.1212/01.wnl.0000340982.01727.6e

348. Du G, Lewis MM, Sen S, *et al.* Imaging nigral pathology and clinical progression in Parkinson's disease. *Mov Disord.* Nov 2012;27(13):1636-43. doi:10.1002/mds.25182

349. Schwarz ST, Abaei M, Gontu V, Morgan PS, Bajaj N, Auer DP. Diffusion tensor imaging of nigral degeneration in Parkinson's disease: A region-of-interest and voxel-based study at 3 T and systematic review with meta-analysis. *Neuroimage Clin.* 2013;3:481-8. doi:10.1016/j.nicl.2013.10.006

350. Schulz J, Pagano G, Fernandez Bonfante JA, Wilson H, Politis M. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. *Brain.* May 1 2018;141(5):1501-1516. doi:10.1093/brain/awy072

351. Ofori E, Pasternak O, Planetta PJ, *et al.* Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. *Neurobiol Aging.* Feb 2015;36(2):1097-104. doi:10.1016/j.neurobiolaging.2014.10.029

352. Burciu RG, Ofori E, Archer DB, *et al.* Progression marker of Parkinson's disease: a 4-year multi-site imaging study. *Brain.* Aug 1 2017;140(8):2183-2192. doi:10.1093/brain/awx146

353. Guttuso T, Jr., Bergsland N, Hagemeier J, Lichter DG, Pasternak O, Zivadinov R. Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease. *AJNR Am J Neuroradiol.* Mar 2018;39(3):479-484. doi:10.3174/ajnr.A5545

354. Archer DB, Bricker JT, Chu WT, *et al.* Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. *Lancet Digit Health.* Sep 2019;1(5):e222-e231. doi:10.1016/s2589-7500(19)30105-0

355. Archer DB, Mitchell T, Burciu RG, *et al.* Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism. *Mov Disord.* Aug 2020;35(8):1388-1395. doi:10.1002/mds.28060

356. Guan J, Rong Y, Wen Y, *et al.* Detection and application of neurochemical profile by multiple regional (1)H-MRS in Parkinson's disease. *Brain Behav.* Sep 2017;7(9):e00792. doi:10.1002/brb3.792

357. Cao H, Shi J, Cao B, Kang B, Zhang M, Qu Q. Evaluation of the Braak staging of brain pathology with (1)H-MRS in patients with Parkinson's disease. *Neurosci Lett.* Nov 1 2017;660:57-62. doi:10.1016/j.neulet.2017.08.050

358.   Tsuda M, Asano S, Kato Y, Murai K, Miyazaki M. Differential diagnosis of multiple system atrophy with predominant parkinsonism and Parkinson's disease using neural networks. *J Neurol Sci*. Jun 15 2019;401:19-26. doi:10.1016/j.jns.2019.04.014

359.   Taylor-Robinson SD, Turjanski N, Bhattacharya S, *et al*. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. *Metab Brain Dis*. Mar 1999;14(1):45-55. doi:10.1023/a:1020609530444

360.   Camicioli RM, Hanstock CC, Bouchard TP, Gee M, Fisher NJ, Martin WR. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease. *Mov Disord*. Feb 15 2007;22(3):382-6. doi:10.1002/mds.21288

361.   Firbank MJ, Harrison RM, O'Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. *Dement Geriatr Cogn Disord*. 2002;14(2):64-76. doi:10.1159/000064927

362.   Groger A, Bender B, Wurster I, Chadzynski GL, Klose U, Berg D. Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging. *J Neurol Neurosurg Psychiatry*. Jun 2013;84(6):644-9. doi:10.1136/jnnp-2012-302699

363.   Iles RA, Stevens AN, Griffiths JR, Morris PG. Phosphorylation status of liver by 31P-n.m.r. spectroscopy, and its implications for metabolic control. A comparison of 31P-n.m.r. spectroscopy (in vivo and in vitro) with chemical and enzymic determinations of ATP, ADP and Pi. *Biochem J*. Jul 1 1985;229(1):141-51. doi:10.1042/bj2290141

364.   Hattingen E, Magerkurth J, Pilatus U, *et al*. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. *Brain*. Dec 2009;132(Pt 12):3285-97. doi:10.1093/brain/awp293

365.   Hu MT, Taylor-Robinson SD, Chaudhuri KR, *et al*. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. *Brain*. Feb 2000;123 (Pt 2):340-52. doi:10.1093/brain/123.2.340

366.   Prasuhn J, Gottlich M, Ebeling B, *et al*. Assessment of Bioenergetic Deficits in Patients With Parkinson Disease and Progressive Supranuclear Palsy Using 31P-MRSI. *Neurology*. Oct 4 2022;doi:10.1212/WNL.0000000000201288

367. Payne T, Appleby M, Buckley E*, et al.* A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease. *Mov Disord*. May 29 2023;doi:10.1002/mds.29450

368. Hacker CD, Perlmutter JS, Criswell SR, Ances BM, Snyder AZ. Resting state functional connectivity of the striatum in Parkinson's disease. *Brain*. Dec 2012;135(Pt 12):3699-711. doi:10.1093/brain/aws281

369. Szewczyk-Krolikowski K, Menke RA, Rolinski M*, et al.* Functional connectivity in the basal ganglia network differentiates PD patients from controls. *Neurology*. Jul 15 2014;83(3):208-14. doi:10.1212/WNL.0000000000000592

370. Baggio HC, Abos A, Segura B*, et al.* Cerebellar resting-state functional connectivity in Parkinson's disease and multiple system atrophy: Characterization of abnormalities and potential for differential diagnosis at the single-patient level. *Neuroimage Clin*. 2019;22:101720. doi:10.1016/j.nicl.2019.101720

371. Burciu RG, Chung JW, Shukla P*, et al.* Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes. *Neurology*. Aug 16 2016;87(7):709-17. doi:10.1212/WNL.0000000000002985

372. Black KJ, Acevedo HK, Koller JM. Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease. *Front Neurol*. 2020;11:370. doi:10.3389/fneur.2020.00370

373. Eberling JL, Dave KD, Frasier MA. alpha-synuclein imaging: a critical need for Parkinson's disease research. *J Parkinsons Dis*. 2013;3(4):565-7. doi:10.3233/JPD-130247

374. Alzghool OM, van Dongen G, van de Giessen E, Schoonmade L, Beaino W. alpha-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives. *Mov Disord*. May 2022;37(5):936-948. doi:10.1002/mds.28984

375. Smith R. Initial clinical scans using [18F]ACI-12589, a novel α-synuclein PET-tracer. *Alzheimer's & Dementia* 2022;18(6)

376. Hutchison RM, Evans KC, Fox T*, et al.* Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. *Bmc Neurology*. Nov 23 2021;21(1)doi:ARTN 459

10.1186/s12883-021-02470-8

377. Nicastro N, Garibotto V, Badoud S, Burkhard PR. Scan without evidence of dopaminergic deficit: A 10-year retrospective study. *Parkinsonism Relat D*. Oct 2016;31:53-58. doi:10.1016/j.parkreldis.2016.07.002

378. Benamer TS, Patterson J, Grosset DG*, et al.* Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. *Mov Disord*. May 2000;15(3):503-10.

379. Hong JY, Sunwoo MK, Oh JS, Kim JS, Sohn YH, Lee PH. Persistent Drug-Induced Parkinsonism in Patients with Normal Dopamine Transporter Imaging. *PLoS One*. 2016;11(6):e0157410. doi:10.1371/journal.pone.0157410

380. Palermo G, Giannoni S, Bellini G, Siciliano G, Ceravolo R. Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review. *International Journal of Molecular Sciences*. Oct 2021;22(20)doi:ARTN 11234

10.3390/ijms222011234

381. Bruck A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO. A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. *Mov Disord*. May 15 2009;24(7):1009-15. doi:10.1002/mds.22484

382. Simuni T, Siderowf A, Lasch S*, et al.* Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. *Mov Disord*. May 2018;33(5):771-782. doi:10.1002/mds.27361

383. Nandhagopal R, Kuramoto L, Schulzer M*, et al.* Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. *Brain*. Nov 2011;134:3290-3298. doi:10.1093/brain/awr233

384. Lee CS, Samii A, Sossi V*, et al.* In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.

Annals of Neurology. Apr 2000;47(4):493-503. doi:Doi 10.1002/1531-8249(200004)47:4<493::Aid-Ana13>3.0.Co;2-4

385.   Perlmutter JS, Norris SA. Neuroimaging Biomarkers for Parkinson Disease: Facts and Fantasy. *Annals of Neurology*. Dec 2014;76(6):769-783. doi:10.1002/ana.24291

386.   Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. *Eur J Pharmacol*. Dec 29 1995;294(2-3):577-83. doi:10.1016/0014-2999(95)00594-3

387.   Stoessl AJ, Lehericy S, Strafella AP. Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. *Lancet*. Aug 9 2014;384(9942):532-544. doi:10.1016/S0140-6736(14)60041-6

388.   Palfi S, Gurruchaga JM, Ralph GS*, et al*. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. *Lancet*. Mar 29 2014;383(9923):1138-46. doi:10.1016/S0140-6736(13)61939-X

389.   Politis M, Wu K, Loane C*, et al*. Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo C-11-DASB PET study. *Neurobiology of Disease*. Oct 2010;40(1):216-221. doi:10.1016/j.nbd.2010.05.028

390.   Fu JF, Matarazzo M, McKenzie J*, et al*. Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia. *Movement Disord*. Feb 2021;36(2):389-397. doi:10.1002/mds.28340

391.   Kotagal V, Spino C, Bohnen NI, Koeppe R, Albin RL. Serotonin, beta-amyloid, and cognition in Parkinson disease. *Ann Neurol*. May 2018;83(5):994-1002. doi:10.1002/ana.25236

392.   Shimada H, Hirano S, Shinotoh H*, et al*. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. *Neurology*. Jul 28 2009;73(4):273-8. doi:10.1212/WNL.0b013e3181ab2b58

393.   Sommerauer M, Fedorova TD, Hansen AK*, et al*. Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. *Brain*. Feb 1 2018;141(2):496-504. doi:10.1093/brain/awx348

394. Matuskey D, Tinaz S, Wilcox KC, *et al*. Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. *Ann Neurol*. Mar 2020;87(3):329-338. doi:10.1002/ana.25682

395. Wilson H, Pagano G, de Natale ER, *et al*. Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease. *Mov Disord*. Aug 2020;35(8):1416-1427. doi:10.1002/mds.28064

396. Delva A, Van Weehaeghe D, Koole M, Van Laere K, Vandenberghe W. Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease. *Mov Disord*. Nov 2020;35(11):1977-1986. doi:10.1002/mds.28216

397. Andersen KB, Hansen AK, Damholdt MF, *et al*. Reduced Synaptic Density in Patients with Lewy Body Dementia: An [(11) C]UCB-J PET Imaging Study. *Mov Disord*. Sep 2021;36(9):2057-2065. doi:10.1002/mds.28617

398. Delva A, Van Laere K, Vandenberghe W. Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease. *Mov Disord*. Sep 2022;37(9):1883-1892. doi:10.1002/mds.29148

399. Eckert T, Barnes A, Dhawan V, *et al*. FDG PET in the differential diagnosis of parkinsonian disorders. *Neuroimage*. Jul 1 2005;26(3):912-21. doi:10.1016/j.neuroimage.2005.03.012

400. Tripathi M, Dhawan V, Peng S, *et al*. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. *Neuroradiology*. Mar 2013;55(4):483-92. doi:10.1007/s00234-012-1132-7

401. Albrecht F, Ballarini T, Neumann J, Schroeter ML. FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson's disease: A whole-brain multimodal imaging meta-analysis. *Neuroimage Clin*. 2019;21:101594. doi:10.1016/j.nicl.2018.11.004

402. Schindlbeck KA, Lucas-Jimenez O, Tang CC, *et al*. Metabolic Network Abnormalities in Drug-Naive Parkinson's Disease. *Mov Disord*. Apr 2020;35(4):587-594. doi:10.1002/mds.27960

403. Tang CC, Poston KL, Eckert T, *et al*. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. *Lancet Neurol*. Feb 2010;9(2):149-58. doi:10.1016/S1474-4422(10)70002-8

404. Huang C, Tang C, Feigin A, *et al*. Changes in network activity with the progression of Parkinson's disease. *Brain*. Jul 2007;130(Pt 7):1834-46. doi:10.1093/brain/awm086

405. Asanuma K, Tang C, Ma Y, *et al*. Network modulation in the treatment of Parkinson's disease. *Brain*. Oct 2006;129(Pt 10):2667-78. doi:10.1093/brain/awl162

406. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. *Trends Neurosci*. Oct 2009;32(10):548-57. doi:10.1016/j.tins.2009.06.003

407. Mattis PJ, Niethammer M, Sako W, *et al*. Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases. *Neurology*. Nov 1 2016;87(18):1925-1933. doi:10.1212/WNL.0000000000003285

408. Niethammer M, Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. *Ann Neurol*. Nov 2012;72(5):635-47. doi:10.1002/ana.23631

409. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. *Neuroimage*. Jan 15 2007;34(2):714-23. doi:10.1016/j.neuroimage.2006.09.003

410. Mizrahi R, Rusjan PM, Kennedy J, *et al*. Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA. *J Cereb Blood Flow Metab*. Jun 2012;32(6):968-72. doi:10.1038/jcbfm.2012.46

411. Ouchi Y, Yoshikawa E, Sekine Y, *et al*. Microglial activation and dopamine terminal loss in early Parkinson's disease. *Ann Neurol*. Feb 2005;57(2):168-75. doi:10.1002/ana.20338

412. Ghadery C, Koshimori Y, Coakeley S, *et al*. Microglial activation in Parkinson's disease using [(18)F]-FEPPA. *J Neuroinflammation*. Jan 11 2017;14(1):8. doi:10.1186/s12974-016-0778-1

413. Saeed U, Lang AE, Masellis M. Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. *Front Neurol*. 2020;11:572976. doi:10.3389/fneur.2020.572976

414. Marek K, Siderowf A, Coffey C, *et al*. Path to Prevention (P2P) - Developing a Prodromal PD Progression Biomarker Program. *Movement Disord*. Oct 2019;34:S64-S64.

415.   Cooper O, Seo H, Andrabi S, *et al*. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. *Sci Transl Med*. Jul 4 2012;4(141):141ra90. doi:10.1126/scitranslmed.3003985

416.   Mullin S, Smith L, Lee K, *et al*. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. *JAMA Neurol*. Apr 1 2020;77(4):427-434. doi:10.1001/jamaneurol.2019.4611

417.   Muller M, Cosman J, Adams J, *et al*. A progress update on the Critical Path for Parkinson's consortium's pre-competitive 3DT initiative. *Movement Disord*. Sep 2022;37:S196-S196.

418.   Tagliapietra M. Aducanumab for the treatment of Alzheimer's disease. *Drugs Today (Barc)*. Oct 2022;58(10):465-477. doi:10.1358/dot.2022.58.10.3422314

Box 1 Fluid and tissue biomarker measurement techniques

ELISA
-target-specific antibodies bind to the sample proteins
-secondary antibody linked to an enzyme recognises the matched antibodies
-fluorescent reaction is created when exposed to a chemical substrate
-amount of antigen present correlates to intensity of colour change
-detection range inferior to other high-sensitivity techniques

Luminex
-beads conjugated with antibody against specific analyte present different colour codes
-high-throughput screening
-can measure up to 80 different proteins or RNA from a single microplate

Mesoscale Discovery
-high-throughput measurement of single or multiple targets
-antibodies can be conjugated to generate electro chemiluminescent signals unlike ELISA

Single Molecule Array
-antibody-based ELISA and bead-based platform
-antibody-coated bead binds to a single molecule and analysed separately
-multiplexing of up to 11 analytes, high sensitivity, and wide detection range

Proximity Extension Assay
-DNA oligonucleotide tags linked to matched antibodies that both bind to target protein
-antibodies come into proximity on binding, DNA duplex formed, sequence amplified
-wide library of matched antibodies with high sensitivity and specificity for their targets

SomaScan
-Aptamers (short, single-stranded DNA or RNA molecules) bind target
-quantified by microarrays or quantitative PCR
-allows creation of library with high sensitivity for targets

Single Molecule Counting
-antibody–antigen sandwich complexes from either beads or plates
-broken up and fluorescently labelled detection antibody counted by laser beam
-allows for a high dynamic concentration range

Mass spectrometry
-measures mass-to-charge ratio of one or more molecules present
-provide quantitative information about composition of complex protein samples
-can also provide information about conformational properties

Microscopy
-used to examine to structure and formation of aggregates

1   -approaches include fluorescence (aggregates labelled with fluorescent probes) microscopy and electron microscopy (resolve
2   oligomer structure at higher resolution)
3 **Seed Amplification Assays**
4   -aggregation assays that detect the presence of protein aggregates
5   -Sample sonication and incubation with recombinant protein monomer
6   -aggregate seeds template and induce aggregation of the excess protein monomers
7   -reaction monitored by a thioflavin readout, aggregation curve characteristics recorded
8 **Extracellular vesicles protein measurement**
9   -released by cells, content represent central nervous system processes
10   -precipitation to increase concentration and neuronal enrichment with immune capture
11   -protein quantification with electrochemiluminescence (e.g. Mesoscale discovery)
12

13 **Table 1 Alpha-synuclein fluid and tissue biomarkers and their potential relevance to clinical trial design**

Biomarker	Origin	Differentiating PD from healthy controls	Marker of disease severity	Differentiating PD from atypical parkinsonism	Predicting disease progression	Surrogate for disease progression
Total alpha synuclein	CSF	−	+	−	−	+
	CSF (Exosomes)		+	+		
	Plasma/Serum	++	−	+		
	Plasma/Serum (Exosomes)	+++	++	++	+	+
	Saliva	+++	+			
	Tears	++	−	−		
	Skin	++	+			
Ser-129p-α-syn	CSF	++	+++	++		+
	Serum/Plasma	+	+		+	
	Tissue/Intestine	++				
	Skin	+		++		
Ratio of phosphorylated α-syn to total α-Syn	CSF	+				
	Saliva(Exosomes)	+			−	
Tyrosine phosphorylated α-syn	CSF	+				
Tyrosine nitrated α-syn	Serum	+				
Oligomeric α-synuclein	CSF	+++	++	+		
	Plasma/Serum/blood	+				
	Serum/plasma (Exosomes)	+	+	+		
	Saliva	+++	−	+		
	Saliva (Exosomes)	+	−			
Ratio of oligomeric to total α-syn	CSF	+++	+	+	+	+
	Plasma/ Serum (Exosomes)	+				
	Saliva	+	−			
	Red blood cells	+	−	−	−	
Oligomeric phosphorylated α-syn species	CSF	+				
	Plasma	+				
α-syn seed amplification	CSF	+++	+	+++		
	Saliva		+			
	GI biopsy	+				
	Skin	++				
	Olfactory mucosa	+		+		

1 Grading approach adapted from [114]. – = No effect (Also scored if negative in a meta-analysis); + = Effect in 1 study/inconsistent results across

2 studies; ++ = Effect in 2-3 studies using single site cohort; +++ = Effect in ≥ 3 studies or multisite cohort (Also scored if positive in meta-

3 analysis).

4

5 **Table 2 Fluid and tissue biomarkers from aberrant pathways noted in PD and their potential relevance to clinical trial design**

Biomarker	Origin	Differentiating PD from healthy controls	Marker of disease severity	Differentiating PD from atypical parkinsonian disorders	Predicting disease progression	Surrogate for disease progression
Neuroinflammation						
Glial Activation Markers (Ykl-40)	CSF	+++		+		
Glial Activation Markers (MCP-1)	CSF	+++	++	+		
GFAP	Serum/Plasma	+	++		+	
T-cell subtype level/ratios	Blood	+++	+++	–	+	
Neutrophil Lymphocyte Ratio	Blood	+++	+			
CRP	Blood	+++	+		+	
Interleukin levels	Blood	+++	+++	–	++	
TNF	Blood	+++	+++		+	
Complement levels	Blood	–	+		+	
Chemokine ligand 5/RANTES	Blood	++	++			
Lysosomal dysfunction						
Glucocerebrosidase activity	CSF	++	+		+	
	Blood	++				
B-hexosaminidase	CSF	+				
cathepsin D	CSF	+				
Glucosylceramide	CSF	–				
	Plasma	++				
	Serum	–				
Mitochondrial dysfunction						
DJ-1	CSF	+	+			
	Plasma/Serum	–	+	+		
Peroxisome proliferator-activated receptor γ coactivator 1α	Blood	++	+			
Fibroblast growth factor 21	Serum	–				
Growth differentiation factor 15	Serum	–				
Synaptic markers						
SNARE Complex	Plasma/Serum (Exosome)	+	–			
SNAP25	CSF	+				
Neurogranin	CSF	+++	++	–	–	
B-synuclein	CSF	–	+	–		
GAP43	CSF	+				
Contactin-1	CSF	+		+		
Pentraxins	CSF	+	+		+	
Neurotransmitter levels	CSF	+		+		
Dopamine metabolites	CSF	+++	+++		+	–

(HVA, DOPAC)	Plasma	++	+			
Axonal damage (NfL)	CSF	–	+	+++	++	
	Plasma/Serum	–	+++	+++	+++	
	Plasma/Serum (Exosome)	–	+			

Grading approach adapted from [114] – = No effect (Also scored if negative in a meta-analysis); + = Effect 1 study/inconsistent results across studies; ++= Effect in 2-3 studies using single site cohort; +++ = Effect in ≥ 3 studies or multisite cohort (Also scored if positive in meta-analysis).

Box 2 Biomarker Imaging Techniques

Transcranial Sonography
   -ultrasound echogenicity measurement of brain tissues or structures through intact cranium -limited by lack of bone window in some subjects, and inter technician variability
Structural MRI
   -quantification of brain structural change using regions-of-interest or whole-brain approaches
   -commonly used sequences include T1, T2, T2*, R2* (R2* = 1/T2*)-weighted, susceptibility-weighted, proton-density-weighted, fluid-attenuated inversion recovery, and neuromelanin-sensitive approaches
Proton Magnetic resonance spectroscopy
   -estimates relative concentrations of proton-containing metabolites in brain
   -metabolites commonly assessed include N-acetylaspartate, choline-containing compounds, myo-inositol, and creatine
Functional MRI
   -evaluates neuronal activity by measuring transient variations in blood flow and variation correlation in functionally connected regions
   -utilized under task-based or under resting-state conditions
Radiotracer imaging
   -Measures pre and post synaptic receptor and transporter density as well as glucose metabolism and microglial activation using different radiotracers
   -provides information on nigrostriatal dopaminergic, serotonergic and cholinergic system integrity, regional tissue glucose metabolism and activity and status of microglial-mediated inflammation

Table 3 outlines the range of imaging biomarkers and their potential relevance to clinical trial design

Imaging modality	Differentiating PD from healthy controls	Marker of disease severity	Differentiating PD from atypical parkinsonian disorders	Predicting disease progression	Surrogate for disease progression
Transcranial Sonography	+	–	+		–
T1 weighted structural MRI	++	+++	+++	++	+++
Neuromelanin MRI	+	+	+		++
Iron Sensitive MRI	+++	+	++	+	+++
Diffusion MRI	+++	++	++	++	++
MR Spectroscopy	+++	++	++		
Functional MRI	++		+		+
PET/SPECT					
Radionuclide					
a-syn	–	–	–		
Dopaminergic	+++	+++	–	–	+++
Non-dopaminergic	++	++		++	
Synaptic density	++	+			–
Metabolic and network imaging					
Glucose metabolism	+++	+	++	++	+
Neuroinflammation	+	+	–		

Grading approach adapted from [114] – = No effect (Also scored if negative in a meta−analysis); + =Effect 1 study/inconsistent results across studies; ++ = Effect in 2−3 studies using single site cohort; +++ Effect in ≥ 3 studies or multisite cohort (Also scored if positive in meta−analysis).